201
|
Li H, Ju Y, Liu WW, Ma YY, Ye H, Li N. [Phase Separation of Purified Human LSM4 Protein]. Mol Biol (Mosk) 2023; 57:124-126. [PMID: 36976747 DOI: 10.31857/s0026898423010068] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2022] [Accepted: 07/20/2022] [Indexed: 03/29/2023]
Abstract
Liquid-liquid phase separation of proteins occur in a number of biological processes, such as regulation of transcription, processing, and RNA maturation. Sm-like protein 4 (LSM4) is involved in multiple processes, including pre-mRNA splicing and P-bodies assembly. Before investigating the involvement of LSM4 in the separation of the two liquid phases during RNA processing or maturation, the separation of the liquid phases in an in vitro preparation of LSM4 protein should be first be detected. The mCherry-LSM4 plasmid was derived from pET30a and used to isolate mCherry-LSM4 protein from prokaryotic cells (Escherichia coli strain BL21). The mCherry LSM4 protein was purified using Ni-NTA resin. The protein was further purified by fast protein liquid chromatography. Delta-Vision wide-field fluorescence microscopy was used to observe the dynamic liquid-liquid phase separation of the LSM4 protein in vitro. Analysis of the LSM4 protein structure using the Predictor of Natural Disordered Regions database revealed that its C-terminus contains a low complexity domain. A purified preparation of full-length human LSM4 protein was obtained from E. coli. Human LSM4 was shown to provide concentration-dependent separation of liquid-liquid phases in vitro in buffer with crowding reagents. Salts in high concentration and 1,6-hexanediol block the LSM4-induced separation of the two liquid phases. In addition, in vitro fusion of LSM4 protein droplets is observed. The results suggest that full-length human LSM4 protein can undergo liquid-liquid phase separation in vitro.
Collapse
|
202
|
Hao B, Xu W, Gao W, Huang T, Lyu L, Lyu D, Xiao H, Li H, Qin J, Sheng L, Liu H. Association between Frailty Assessed Using Two Electronic Medical Record-Based Frailty Assessment Tools and Long-Term Adverse Prognosis in Older Critically Ill Survivors. J Nutr Health Aging 2023; 27:649-655. [PMID: 37702338 DOI: 10.1007/s12603-023-1961-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2023] [Accepted: 07/20/2023] [Indexed: 09/14/2023]
Abstract
OBJECTIVES Frailty has become an independent risk factor for adverse outcomes in critically ill patients. This study aimed to explore the predictive ability of two electronic medical record-based frailty assessment tools, the Hospital Frailty Risk Score (HFRS) and Frailty Index based on physiological and laboratory tests (FI-lab), for long-term adverse prognosis in older critically ill survivors. DESIGN Retrospective observational study. SETTING AND PARTICIPANTS 9,082 critically ill survivors aged ≥ 65 years. MEASUREMENTS The HFRS and the 33-item FI-lab were constructed based on the published literature. Cox and logistic regression models assessed the association between frailty and 1-year mortality and post-discharge care needs. RESULTS 2,586 patients died within 1 year of follow-up. In fully adjusted models, frailty assessed using both the HFRS (per point, hazard ratio [HR] 1.06, 95% confidential interval [CI] 1.05-1.06; intermediate frailty risk, HR 2.00, 95% CI 1.78-2.25; high frailty risk, HR 3.06, 95% CI 2.68-3.50) and FI-lab (per 0.01 points, HR 1.03, 95% CI 1.03-1.03; intermediate frailty risk, HR 1.59, 95% CI 1.44-1.76; high frailty risk, HR 2.30, 95% CI 2.06-2.57) was associated with mortality. Addition of frailty indicators improved the predictive validity of the Sequential Organ Failure Assessment score for mortality (HFRS alone ∆ C-index 0.034; FI-lab alone ∆ C-index 0.016; HFRS and FI-lab combined ∆ C-index 0.042). The HFRS but not the FI-lab was associated with higher probability of post-discharge care needs. CONCLUSION Both the HFRS and FI-lab could independently predict 1-year mortality in older critically ill survivors. Adding the HFRS to the SOFA score model improved it more than adding the FI-lab. The greatest improvement was achieved when both frailty indicators were used together. These findings suggest that electronic medical record-based frailty assessment methods can be useful tools for predicting long-term outcomes in older critically ill patients.
Collapse
|
203
|
Tong JL, Zhu GH, Sun DW, Lu D, Cheng YF, Chen H, Pei LJ, Yin X, Zhou WD, Zhang W, Ling D, Xie X, Tan X, Zhu YJ, Wu XM, Hu CY, Li H, Wang Y, Fan JY, Jia XM, Zhu TY, Chen LM, Guo HY, Zhao SJ, Wang S, Feng SW, He XY, Chi YG, Sun XL, Lang JH, Sui L, Zhu L. [Consensus of Chinese experts on hysteroscopy day surgery center set-up and management process]. ZHONGHUA FU CHAN KE ZA ZHI 2022; 57:891-899. [PMID: 36562222 DOI: 10.3760/cma.j.cn112141-20220925-00594] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
|
204
|
Liu C, Meng Q, Zu C, Li R, Yang S, He P, Li H, Zhang YY, Zhou C, Liu M, Ye Z, Wu Q, Zhang YJ, Gan X, Qin X. U-shaped association between dietary thiamine intake and new-onset diabetes: a nationwide cohort study. QJM 2022; 115:822-829. [PMID: 35894803 PMCID: PMC9744247 DOI: 10.1093/qjmed/hcac159] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/07/2022] [Revised: 06/25/2022] [Indexed: 02/02/2023] Open
Abstract
BACKGROUND The association between dietary thiamine intake and the risk of diabetes remains unknown. AIM We aimed to evaluate the relation of dietary thiamine intake with new-onset diabetes and examine possible effect modifiers. DESIGN Prospective cohort study. METHODS A total of 16 272 participants who were free of diabetes at baseline were enrolled from China Health and Nutrition Survey (CHNS). Dietary nutrients intake information was collected by 3-day dietary recalls in addition to using a 3-day food-weighed method to assess cooking oil and condiment consumption. New-onset diabetes was defined as a fasting blood glucose ≥7.0 mmol/l or a glycated haemoglobin (HbA1c) ≥6.5% (48 mmol/mol) or diagnosed by a physician during the follow-up. RESULTS During a median follow-up duration of 9.0 years, new-onset diabetes occurred in 1101 participants. Overall, the association between dietary thiamine intake and new-onset diabetes followed a U-shape (P for non-linearity <0.001). Consistently, when thiamine intake was assessed as quartiles, compared with those in the 2-3 quartiles (0.75 to 1.10 mg/day), the significantly higher risks of new-onset diabetes were found in participants in the first quartile [adjusted hazard ratio (HR), 1.33; 95% confidence interval (CI): 1.10, 1.61] and the fourth quartile (adjusted HR, 1.39; 95% CI: 1.17, 1.67). Similar results were found when further adjusting for the intake of other major nutrients or food groups; or using the propensity score weighting to control the imbalance of covariates. CONCLUSION Our results suggested that there was a U-shape association between dietary thiamine intake and new-onset diabetes in general Chinese adults, with a minimal risk at 0.75-1.10 mg/day.
Collapse
|
205
|
Zhao S, Li H, Hua HJ, Zhu Y. [Clinicopathological diagnosis of hepatic inflammatory pseudotumor-like follicular dendritic cell sarcoma in needle biopsy specimens]. ZHONGHUA BING LI XUE ZA ZHI = CHINESE JOURNAL OF PATHOLOGY 2022; 51:1263-1265. [PMID: 36480839 DOI: 10.3760/cma.j.cn112151-20220926-00809] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
206
|
Zhao L, Li H, He YY, Wang K, Wang J, Yan DG, Ni S, Zhu YM, Liu SY. [Analysis of surgical strategy for pediatric papillary thyroid carcinoma with low-intermediate risk]. ZHONGHUA ER BI YAN HOU TOU JING WAI KE ZA ZHI = CHINESE JOURNAL OF OTORHINOLARYNGOLOGY HEAD AND NECK SURGERY 2022; 57:1396-1402. [PMID: 36707942 DOI: 10.3760/cma.j.cn115330-20220511-00261] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Objective: To explore the feasibility and rationality of lobectomy in the treatment of pediatric thyroid papillary carcinoma (PTC) with low-intermediate risk. Methods: The clinicopathological features and follow-up data of pediatric PTC with low-intermediate risk were reviewed from March 2000 to December 2018 in Cancer Hospital of Chinese Academy of Medical Sciences. The correlations between different surgical procedures and prognoses were evaluated. Propensity score matching(PSM) was used to adjust for risk factors, and the difference in prognoses between the total thyroidectomy (TT) group and the lobectomy (LT) group was compared. Results: A total of 140 patients were included in the study, including 36 males and 104 females. The age range was from 6-year-old to 18-year-old. There were 43 low-risk patients and 97 intermediate-risk patients. The median follow-up time was 87.5 months, ranging from 8 to 241 months, and 20 patients (14.3%) showed recurrence during the follow-up period. Univariate analysis showed that N1b, extrathyroidal extension, the number of lymph node metastasis>5, the ratio of lymph node metastasis≥0.19, and radioactive iodine treatment were risk factors for recurrence (all P value below 0.05), but multivariate analysis showed that only the ratio of lymph node metastasis≥0.19 (HR=8.69, 95%CI=1.08-70.21, P=0.043) was an independent risk factor for recurrence. There was no significant difference in the 5-year recurrence free survival rates between TT group and LT group before propensity score matching (82.8% vs. 86.5%, χ2=0.219, P=0.640) and after propensity score matching (89.6% vs. 90.4%, χ2=0.099, P=0.753). Conclusion: There is no significant difference in recurrence-free survival between TT group and LT group. Lobectomy is feasible for selective pediatric PTC with low-intermediate risk.
Collapse
|
207
|
Ablikim M, Achasov MN, Adlarson P, Albrecht M, Aliberti R, Amoroso A, An MR, An Q, Bai XH, Bai Y, Bakina O, Baldini Ferroli R, Balossino I, Ban Y, Batozskaya V, Becker D, Begzsuren K, Berger N, Bertani M, Bettoni D, Bianchi F, Bloms J, Bortone A, Boyko I, Briere RA, Brueggemann A, Cai H, Cai X, Calcaterra A, Cao GF, Cao N, Cetin SA, Chang JF, Chang WL, Chelkov G, Chen C, Chen C, Chen G, Chen HS, Chen ML, Chen SJ, Chen SM, Chen T, Chen XR, Chen XT, Chen YB, Chen ZJ, Cheng WS, Choi SK, Chu X, Cibinetto G, Cossio F, Cui JJ, Dai HL, Dai JP, Dbeyssi A, de Boer RE, Dedovich D, Deng ZY, Denig A, Denysenko I, Destefanis M, De Mori F, Ding Y, Dong J, Dong LY, Dong MY, Dong X, Du SX, Egorov P, Fan YL, Fang J, Fang SS, Fang WX, Fang Y, Farinelli R, Fava L, Feldbauer F, Felici G, Feng CQ, Feng JH, Fischer K, Fritsch M, Fritzsch C, Fu CD, Gao H, Gao YN, Gao Y, Garbolino S, Garzia I, Ge PT, Ge ZW, Geng C, Gersabeck EM, Gilman A, Goetzen K, Gong L, Gong WX, Gradl W, Greco M, Gu LM, Gu MH, Gu YT, Guan CY, Guo AQ, Guo LB, Guo RP, Guo YP, Guskov A, Han TT, Han WY, Hao XQ, Harris FA, He KK, He KL, Heinsius FH, Heinz CH, Heng YK, Herold C, Himmelreich M, Hou GY, Hou YR, Hou ZL, Hu HM, Hu JF, Hu T, Hu Y, Huang GS, Huang KX, Huang LQ, Huang LQ, Huang XT, Huang YP, Huang Z, Hussain T, Hüsken N, Imoehl W, Irshad M, Jackson J, Jaeger S, Janchiv S, Jang E, Jeong JH, Ji Q, Ji QP, Ji XB, Ji XL, Ji YY, Jia ZK, Jiang HB, Jiang SS, Jiang XS, Jiang Y, Jiao JB, Jiao Z, Jin S, Jin Y, Jing MQ, Johansson T, Kalantar-Nayestanaki N, Kang XS, Kappert R, Kavatsyuk M, Ke BC, Keshk IK, Khoukaz A, Kiese P, Kiuchi R, Kliemt R, Koch L, Kolcu OB, Kopf B, Kuemmel M, Kuessner M, Kupsc A, Kühn W, Lane JJ, Lange JS, Larin P, Lavania A, Lavezzi L, Lei ZH, Leithoff H, Lellmann M, Lenz T, Li C, Li C, Li CH, Li C, Li DM, Li F, Li G, Li H, Li H, Li HB, Li HJ, Li HN, Li JQ, Li JS, Li JW, Li K, Li LJ, Li LK, Li L, Li MH, Li PR, Li SX, Li SY, Li T, Li WD, Li WG, Li XH, Li XL, Li X, Liang H, Liang H, Liang H, Liang YF, Liang YT, Liao GR, Liao LZ, Libby J, Limphirat A, Lin CX, Lin DX, Lin T, Liu BJ, Liu CX, Liu D, Liu FH, Liu F, Liu F, Liu GM, Liu H, Liu HB, Liu HM, Liu H, Liu H, Liu JB, Liu JL, Liu JY, Liu K, Liu KY, Liu K, Liu L, Liu MH, Liu PL, Liu Q, Liu SB, Liu T, Liu WK, Liu WM, Liu X, Liu Y, Liu YB, Liu ZA, Liu ZQ, Lou XC, Lu FX, Lu HJ, Lu JG, Lu XL, Lu Y, Lu YP, Lu ZH, Luo CL, Luo MX, Luo T, Luo XL, Lyu XR, Lyu YF, Ma FC, Ma HL, Ma LL, Ma MM, Ma QM, Ma RQ, Ma RT, Ma XY, Ma Y, Maas FE, Maggiora M, Maldaner S, Malde S, Malik QA, Mangoni A, Mao YJ, Mao ZP, Marcello S, Meng ZX, Messchendorp JG, Mezzadri G, Miao H, Min TJ, Mitchell RE, Mo XH, Muchnoi NY, Nefedov Y, Nerling F, Nikolaev IB, Ning Z, Nisar S, Niu Y, Olsen SL, Ouyang Q, Pacetti S, Pan X, Pan Y, Pathak A, Pelizaeus M, Peng HP, Peters K, Pettersson J, Ping JL, Ping RG, Plura S, Pogodin S, Prasad V, Qi FZ, Qi H, Qi HR, Qi M, Qi TY, Qian S, Qian WB, Qian Z, Qiao CF, Qin JJ, Qin LQ, Qin XP, Qin XS, Qin ZH, Qiu JF, Qu SQ, Rashid KH, Redmer CF, Ren KJ, Rivetti A, Rodin V, Rolo M, Rong G, Rosner C, Ruan SN, Sang HS, Sarantsev A, Schelhaas Y, Schnier C, Schönning K, Scodeggio M, Shan KY, Shan W, Shan XY, Shangguan JF, Shao LG, Shao M, Shen CP, Shen HF, Shen XY, Shi BA, Shi HC, Shi JY, Shi QQ, Shi RS, Shi X, Shi XD, Song JJ, Song WM, Song YX, Sosio S, Spataro S, Stieler F, Su KX, Su PP, Su YJ, Sun GX, Sun H, Sun HK, Sun JF, Sun L, Sun SS, Sun T, Sun WY, Sun X, Sun YJ, Sun YZ, Sun ZT, Tan YH, Tan YX, Tang CJ, Tang GY, Tang J, Tao LY, Tao QT, Tat M, Teng JX, Thoren V, Tian WH, Tian Y, Uman I, Wang B, Wang BL, Wang CW, Wang DY, Wang F, Wang HJ, Wang HP, Wang K, Wang LL, Wang M, Wang MZ, Wang M, Wang S, Wang T, Wang TJ, Wang W, Wang WH, Wang WP, Wang X, Wang XF, Wang XL, Wang Y, Wang YD, Wang YF, Wang YH, Wang YQ, Wang Y, Wang Z, Wang ZY, Wang Z, Wei DH, Weidner F, Wen SP, White DJ, Wiedner U, Wilkinson G, Wolke M, Wollenberg L, Wu JF, Wu LH, Wu LJ, Wu X, Wu XH, Wu Y, Wu Z, Xia L, Xiang T, Xiao D, Xiao GY, Xiao H, Xiao SY, Xiao YL, Xiao ZJ, Xie C, Xie XH, Xie Y, Xie YG, Xie YH, Xie ZP, Xing TY, Xu CF, Xu CJ, Xu GF, Xu HY, Xu QJ, Xu SY, Xu XP, Xu YC, Xu ZP, Yan F, Yan L, Yan WB, Yan WC, Yang HJ, Yang HL, Yang HX, Yang L, Yang SL, Yang T, Yang YX, Yang Y, Ye M, Ye MH, Yin JH, You ZY, Yu BX, Yu CX, Yu G, Yu T, Yuan CZ, Yuan L, Yuan SC, Yuan XQ, Yuan Y, Yuan ZY, Yue CX, Zafar AA, Zeng FR, Zeng X, Zeng Y, Zhan YH, Zhang AQ, Zhang BL, Zhang BX, Zhang DH, Zhang GY, Zhang H, Zhang HH, Zhang HH, Zhang HY, Zhang JL, Zhang JQ, Zhang JW, Zhang JX, Zhang JY, Zhang JZ, Zhang J, Zhang J, Zhang LM, Zhang LQ, Zhang L, Zhang P, Zhang QY, Zhang S, Zhang XD, Zhang XM, Zhang XY, Zhang XY, Zhang Y, Zhang YT, Zhang YH, Zhang Y, Zhang Y, Zhang ZH, Zhang ZY, Zhang ZY, Zhao G, Zhao J, Zhao JY, Zhao JZ, Zhao L, Zhao L, Zhao MG, Zhao Q, Zhao SJ, Zhao YB, Zhao YX, Zhao ZG, Zhemchugov A, Zheng B, Zheng JP, Zheng YH, Zhong B, Zhong C, Zhong X, Zhou H, Zhou LP, Zhou X, Zhou XK, Zhou XR, Zhou XY, Zhou YZ, Zhu J, Zhu K, Zhu KJ, Zhu LX, Zhu SH, Zhu SQ, Zhu TJ, Zhu WJ, Zhu YC, Zhu ZA, Zou BS, Zou JH. Study of the Semileptonic Decay Λ_{c}^{+}→Λe^{+}ν_{e}. PHYSICAL REVIEW LETTERS 2022; 129:231803. [PMID: 36563214 DOI: 10.1103/physrevlett.129.231803] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/28/2022] [Accepted: 11/01/2022] [Indexed: 06/17/2023]
Abstract
The study of the Cabibbo-favored semileptonic decay Λ_{c}^{+}→Λe^{+}ν_{e} is reported using a 4.5 fb^{-1} data sample of e^{+}e^{-} annihilations collected at center-of-mass energies ranging from 4.600 GeV to 4.699 GeV with the BESIII detector at the BEPCII collider. The branching fraction of the decay is measured to be B(Λ_{c}^{+}→Λe^{+}ν_{e})=(3.56±0.11_{stat}±0.07_{syst})%, which is the most precise measurement to date. Furthermore, we perform an investigation of the internal dynamics in Λ_{c}^{+}→Λe^{+}ν_{e}. We provide the first direct comparisons of the differential decay rate and form factors with those predicted from lattice quantum chromodynamics (LQCD) calculations. Combining the measured branching fraction with a q^{2}-integrated rate predicted by LQCD, we determine |V_{cs}|=0.936±0.017_{B}±0.024_{LQCD}±0.007_{τ_{Λ_{c}}}.
Collapse
|
208
|
Fan Y, Li H, Zhang Y, Xu Y, Huang Z, Chen G. 204P Tumor immune microenvironment and immunotherapy efficacy in BRAF mutation non-small cell lung cancer. IMMUNO-ONCOLOGY AND TECHNOLOGY 2022. [DOI: 10.1016/j.iotech.2022.100315] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
209
|
Cao LS, Xu H, Li H. Effect of Greening Trees on Thermal Comfort of the Pedestrian Streets in Hot Summer and Cold Winter Regions in China. NATURE ENVIRONMENT AND POLLUTION TECHNOLOGY 2022. [DOI: 10.46488/nept.2022.v21i04.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/03/2022] Open
Abstract
The thermal environment problems of pedestrian streets space are becoming increasingly important with the growing rate of urbanization, especially in regions with hot summers and cold winters. Taking Cinnamomum camphora as an example, several urban design scenarios with dynamic setting parameters of streets orientation (N-S, E-W), aspect ratio (0.5, 1,1.5, 2) are simulated by ENVI-met to analyze the impact of the green coverage on the thermal comfort of the street canyons in Shanghai. Results showed that: (1) green coverage has an impact on the thermal comfort of the street both in summer and winter and the significance of this effect is affected by the orientation and aspect ratio of the streets. (2) In summer, with the increase in aspect ratio, N-S orientation streets need more and more green coverage to bring a significant impact on thermal comfort, while E-W orientation streets only need 24 % green coverage. (3) In winter, with the increase in aspect ratio, N-S orientation streets also need more green coverage to significantly reduce thermal comfort. For E-W orientation, only when the aspect ratio is 1/2, the green coverage can effectively reduce the thermal comfort of the street. (4) The planting layout had no significant effect on the thermal comfort effect of trees. Based on the above conclusions, the greening strategy was proposed for pedestrian streets in the hot summer and cold winter region in China.
Collapse
|
210
|
Xu Y, Li H, Huang Z, Xie M, Zhou Z, Fan Y. 33P Changes in serum cytokine CXCL12 level can predict the survival of patients with non-small cell lung cancer receiving anti-PD-1 treatment. IMMUNO-ONCOLOGY AND TECHNOLOGY 2022. [DOI: 10.1016/j.iotech.2022.100138] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
|
211
|
Li H, Shen J, Zhang Y, Hu L, Luo W. 6-Shogaol protects against isoproterenol-induced cardiac injury in rats through attenutating oxidative stress, inflammation, apoptosis and activating nuclear respiratory factor-2/heme oxygenase-1 signaling pathway. JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY : AN OFFICIAL JOURNAL OF THE POLISH PHYSIOLOGICAL SOCIETY 2022; 73. [PMID: 37087565 DOI: 10.26402/jpp.2022.6.06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Subscribe] [Scholar Register] [Received: 08/23/2022] [Accepted: 12/31/2022] [Indexed: 04/24/2023]
Abstract
The current study investigated the preventive effect of 6-Shogaol on isoproterenol hydrochloride (ISO)-induced myocardial cardiac injury. 6-Shogaol (50 mg/kg b.w.) was administered for 14 days at pretreatment and ISO-induction (85 mg/kg b.w.) for the last two days (13th and 14th days) by subcutaneous injection. Cardiac markers in serum like creatine kinase (CK), creatine kinase-MB (CK-MB), lactate dehydrogenase (LDH), cardiac troponins T (cTn T) and I (cTn I) increased in ISO-induced rats. Moreover, lipid peroxidative markers like thiobarbituric acid reactive substances (TBARS) and lipid hydroperoxides (LOOH) were raised, and the activities/level of superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx) and reduced glutathione (GSH) were diminished in ISO-treated heart tissue. In addition, inflammatory and nuclear respiratory factor (Nrf)-2 signalling molecules were upregulated in ISO-induced ischemic rats. 6-Shogaol pretreatment decreased the activities of cardiac and lipid peroxidative markers and enhanced the antioxidant status in ISO-induced cardiac injury rats. Further, 6-Shogaol pretreatment inhibited serum inflammatory markers: tumour necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), nuclear factor-kappaB (NF-κB), Nrf-2 molecule and heme oxygenase (HO)-1 in ISO-induced cardial damage rats. We noticed the effect of 6-Shogaol inhibited pro-apoptotic genes like B-cell lymphoma 2 (Bcl-2)-associated X protein (Bax), Fas, caspase-3, -8, -9, cytochrome C, and inflammatory genes and increased Bcl-2 expression in ISO-treated rats. The cardioprotective activity of 6-Shogaol in rats with ISO-induced myocardial damage may be due to its ability to reduce oxidative stress, inflammation, and apoptosis, perhaps via the Nrf-2/HO-1 signalling pathway.
Collapse
|
212
|
Duan X, Li H, Kuang D, Zhang M, Xu W, Liang C, Wang J, Ren J. 143P Efficacy and safety of bronchial arterial chemoembolization (BACE) in combination with tislelizumab for non-small cell lung cancer (NSCLC): A single-arm phase II trial. IMMUNO-ONCOLOGY AND TECHNOLOGY 2022. [DOI: 10.1016/j.iotech.2022.100255] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
|
213
|
Bai W, Sun M, Song H, Li H, Xu X, Chen X, Zhao Y, Chen B, Yao S, Xu Q, Wei S, Zhou H, Yu S. Serial analyses of clinical spectra and outcomes in Chinese women with pregnancy-induced optic neuritis. Front Med (Lausanne) 2022; 9:1067277. [PMID: 36507533 PMCID: PMC9733704 DOI: 10.3389/fmed.2022.1067277] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2022] [Accepted: 11/04/2022] [Indexed: 11/27/2022] Open
Abstract
Objective This study aimed to investigate the clinical spectra and outcomes in pregnancy-related optic neuritis (ON). Methods We analyzed the clinical subtype and prognosis of women with pregnancy-related ON in the neuro-ophthalmology department of the First Medical Center at the Chinese PLA General Hospital from January 2014 to December 2019. Results A total of 54 patients, including 21 (38.9%) with idiopathic ON (ION), 27 (50.0%) with aquaporin-4 (AQP4)-ON, and 6 (11.6%) with myelin oligodendrocyte glycoprotein (MOG)-ON, who experienced 58 informative pregnancies and 67 episodes of pregnancy-related ON were assessed. Among the ON attacks, there were 11 (16.4%) during pregnancy and 56 (83.6%) within 1 year postpartum (PP1) or after abortion, including 33 (49.3%) in the first trimester. In total, 14 (25.9%) patients with ON onset before pregnancy had a higher relapse rate during PP1 than within 1 year before pregnancy (p = 0.021), and 24 (85.7%) eyes with ION and nine (100%) with MOG-ON had significantly better visual outcomes (p ≥ 0.5) than those with AQP4-ON (14, 35%) (p < 0.001 and p < 0.001, respectively). Two AQP4-ON patients had premature birth and low baby weight, respectively. There were no birth defects or stillbirths. Conclusion The significantly increased relapse rate and numerous cases of ON after pregnancy suggest that delivery adversely affects the course of ON.
Collapse
|
214
|
He LN, Fu S, Ma H, Chen C, Zhang X, Li H, Du W, Chen T, Jiang Y, Wang Y, Wang Y, Zhou Y, Lin Z, Yang Y, Huang Y, Zhao H, Fang W, Zhang H, Zhang L, Hong S. Early on-treatment tumor growth rate (EOT-TGR) determines treatment outcomes of advanced non-small-cell lung cancer patients treated with programmed cell death protein 1 axis inhibitor. ESMO Open 2022; 7:100630. [PMID: 36442353 PMCID: PMC9808481 DOI: 10.1016/j.esmoop.2022.100630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2022] [Revised: 10/02/2022] [Accepted: 10/09/2022] [Indexed: 11/27/2022] Open
Abstract
BACKGROUND Tumor growth rate (TGR), denoted as percentage change in tumor size per month, is a well-established indicator of tumor growth kinetics. The predictive value of early on-treatment TGR (EOT-TGR) for immunotherapy remains unclear. We sought to establish and validate the association of EOT-TGR with treatment outcomes in patients with advanced non-small-cell lung cancer (aNSCLC) undergoing anti-PD-1/PD-L1 (programmed cell death protein 1/programmed death-ligand 1) therapy. PATIENTS AND METHODS This bicenter retrospective cohort study included a training cohort, a contemporaneously treated internal validation cohort, and an external validation cohort. Computed tomography images were retrieved to calculate EOT-TGR, denoted as tumor burden change per month during a period between baseline and the first imaging evaluation after immunotherapy. Kaplan-Meier methodology and Cox regression analysis were conducted for survival analyses. RESULTS In the pooled cohort (n = 172), 125 patients (72.7%) were males; median age at diagnosis was 58 (range 28-79) years. Based on the training cohort, we determined the optimal cut-off value for EOT-TGR as 10.4%/month. Higher EOT-TGR was significantly associated with inferior overall survival [OS; hazard ratio (HR) 2.93, 95% confidence interval (CI) 1.47-5.83; P = 0.002], worse progression-free survival (PFS; HR 2.44, 95% CI 1.46-4.08; P = 0.001), and lower objective response rate (3.3% versus 20.9%; P = 0.040) and durable clinical benefit rate (6.7% versus 41.9%; P = 0.001). Results were reproducible in the two validation cohorts for OS and PFS. Among 43 patients who had a best response of progressive disease in the training cohort, those with high EOT-TGR had worse OS (HR 2.64; P = 0.041) and were more likely to progress due to target lesions at the first tumor evaluation (85.2% versus 0.0%; P <0.001). CONCLUSIONS Higher EOT-TGR was associated with inferior OS and immunotherapeutic response in patients with aNSCLC undergoing anti-PD-1/PD-L1 therapy. This easy-to-calculate radiologic biomarker may help evaluate the abilities of immunotherapy to prolong survival and assist in tailoring patients' management. TRIAL REGISTRATION ClinicalTrials.govNCT04722406; https://clinicaltrials.gov/ct2/show/NCT04722406.
Collapse
|
215
|
Ablikim M, Achasov MN, Adlarson P, Albrecht M, Aliberti R, Amoroso A, An MR, An Q, Bai XH, Bai Y, Bakina O, Baldini Ferroli R, Balossino I, Ban Y, Batozskaya V, Becker D, Begzsuren K, Berger N, Bertani M, Bettoni D, Bianchi F, Bloms J, Bortone A, Boyko I, Briere RA, Brueggemann A, Cai H, Cai X, Calcaterra A, Cao GF, Cao N, Cetin SA, Chang JF, Chang WL, Chelkov G, Chen C, Chen C, Chen G, Chen HS, Chen ML, Chen SJ, Chen SM, Chen T, Chen XR, Chen XT, Chen YB, Chen ZJ, Cheng WS, Choi SK, Chu X, Cibinetto G, Cossio F, Cui JJ, Dai HL, Dai JP, Dbeyssi A, de Boer RE, Dedovich D, Deng ZY, Denig A, Denysenko I, Destefanis M, De Mori F, Ding Y, Dong J, Dong LY, Dong MY, Dong X, Du SX, Egorov P, Fan YL, Fang J, Fang SS, Fang WX, Fang Y, Farinelli R, Fava L, Feldbauer F, Felici G, Feng CQ, Feng JH, Fischer K, Fritsch M, Fritzsch C, Fu CD, Gao H, Gao YN, Gao Y, Garbolino S, Garzia I, Ge PT, Ge ZW, Geng C, Gersabeck EM, Gilman A, Goetzen K, Gong L, Gong WX, Gradl W, Greco M, Gu LM, Gu MH, Gu YT, Guan CY, Guo AQ, Guo LB, Guo RP, Guo YP, Guskov A, Han TT, Han WY, Hao XQ, Harris FA, He KK, He KL, Heinsius FH, Heinz CH, Heng YK, Herold C, Himmelreich M, Hou GY, Hou YR, Hou ZL, Hu HM, Hu JF, Hu T, Hu Y, Huang GS, Huang KX, Huang LQ, Huang LQ, Huang XT, Huang YP, Huang Z, Hussain T, Hüsken N, Imoehl W, Irshad M, Jackson J, Jaeger S, Janchiv S, Jang E, Jeong JH, Ji Q, Ji QP, Ji XB, Ji XL, Ji YY, Jia ZK, Jiang HB, Jiang SS, Jiang XS, Jiang Y, Jiao JB, Jiao Z, Jin S, Jin Y, Jing MQ, Johansson T, Kalantar-Nayestanaki N, Kang XS, Kappert R, Kavatsyuk M, Ke BC, Keshk IK, Khoukaz A, Kiese P, Kiuchi R, Kliemt R, Koch L, Kolcu OB, Kopf B, Kuemmel M, Kuessner M, Kupsc A, Kühn W, Lane JJ, Lange JS, Larin P, Lavania A, Lavezzi L, Lei ZH, Leithoff H, Lellmann M, Lenz T, Li C, Li C, Li CH, Li C, Li DM, Li F, Li G, Li H, Li H, Li HB, Li HJ, Li HN, Li JQ, Li JS, Li JW, Li K, Li LJ, Li LK, Li L, Li MH, Li PR, Li SX, Li SY, Li T, Li WD, Li WG, Li XH, Li XL, Li X, Liang H, Liang H, Liang H, Liang YF, Liang YT, Liao GR, Liao LZ, Libby J, Limphirat A, Lin CX, Lin DX, Lin T, Liu BJ, Liu CX, Liu D, Liu FH, Liu F, Liu F, Liu GM, Liu H, Liu HB, Liu HM, Liu H, Liu H, Liu JB, Liu JL, Liu JY, Liu K, Liu KY, Liu K, Liu L, Liu L, Liu MH, Liu PL, Liu Q, Liu SB, Liu T, Liu WK, Liu WM, Liu X, Liu Y, Liu YB, Liu ZA, Liu ZQ, Lou XC, Lu FX, Lu HJ, Lu JG, Lu XL, Lu Y, Lu YP, Lu ZH, Luo CL, Luo MX, Luo T, Luo XL, Lyu XR, Lyu YF, Ma FC, Ma HL, Ma LL, Ma MM, Ma QM, Ma RQ, Ma RT, Ma XY, Ma Y, Maas FE, Maggiora M, Maldaner S, Malde S, Malik QA, Mangoni A, Mao YJ, Mao ZP, Marcello S, Meng ZX, Messchendorp J, Mezzadri G, Miao H, Min TJ, Mitchell RE, Mo XH, Muchnoi NY, Nefedov Y, Nerling F, Nikolaev IB, Ning Z, Nisar S, Niu Y, Olsen SL, Ouyang Q, Pacetti S, Pan X, Pan Y, Pathak A, Pelizaeus M, Peng HP, Peters K, Ping JL, Ping RG, Plura S, Pogodin S, Prasad V, Qi FZ, Qi H, Qi HR, Qi M, Qi TY, Qian S, Qian WB, Qian Z, Qiao CF, Qin JJ, Qin LQ, Qin XP, Qin XS, Qin ZH, Qiu JF, Qu SQ, Qu SQ, Rashid KH, Redmer CF, Ren KJ, Rivetti A, Rodin V, Rolo M, Rong G, Rosner C, Ruan SN, Sang HS, Sarantsev A, Schelhaas Y, Schnier C, Schoenning K, Scodeggio M, Shan KY, Shan W, Shan XY, Shangguan JF, Shao LG, Shao M, Shen CP, Shen HF, Shen XY, Shi BA, Shi HC, Shi JY, Shi QQ, Shi RS, Shi X, Shi XD, Song JJ, Song WM, Song YX, Sosio S, Spataro S, Stieler F, Su KX, Su PP, Su YJ, Sun GX, Sun H, Sun HK, Sun JF, Sun L, Sun SS, Sun T, Sun WY, Sun X, Sun YJ, Sun YZ, Sun ZT, Tan YH, Tan YX, Tang CJ, Tang GY, Tang J, Tao LY, Tao QT, Tat M, Teng JX, Thoren V, Tian WH, Tian Y, Uman I, Wang B, Wang BL, Wang CW, Wang DY, Wang F, Wang HJ, Wang HP, Wang K, Wang LL, Wang M, Wang MZ, Wang M, Wang S, Wang S, Wang T, Wang TJ, Wang W, Wang WH, Wang WP, Wang X, Wang XF, Wang XL, Wang Y, Wang YD, Wang YF, Wang YH, Wang YQ, Wang Y, Wang Z, Wang ZY, Wang Z, Wei DH, Weidner F, Wen SP, White DJ, Wiedner U, Wilkinson G, Wolke M, Wollenberg L, Wu JF, Wu LH, Wu LJ, Wu X, Wu XH, Wu Y, Wu YJ, Wu Z, Xia L, Xiang T, Xiao D, Xiao GY, Xiao H, Xiao SY, Xiao YL, Xiao ZJ, Xie C, Xie XH, Xie Y, Xie YG, Xie YH, Xie ZP, Xing TY, Xu CF, Xu CJ, Xu GF, Xu HY, Xu QJ, Xu XP, Xu YC, Xu ZP, Yan F, Yan L, Yan WB, Yan WC, Yang HJ, Yang HL, Yang HX, Yang L, Yang SL, Yang T, Yang YF, Yang YX, Yang Y, Ye M, Ye MH, Yin JH, You ZY, Yu BX, Yu CX, Yu G, Yu T, Yuan CZ, Yuan L, Yuan SC, Yuan XQ, Yuan Y, Yuan ZY, Yue CX, Zafar AA, Zeng FR, Zeng X, Zeng Y, Zhan YH, Zhang AQ, Zhang BL, Zhang BX, Zhang DH, Zhang GY, Zhang H, Zhang HH, Zhang HH, Zhang HY, Zhang JL, Zhang JQ, Zhang JW, Zhang JX, Zhang JY, Zhang JZ, Zhang J, Zhang J, Zhang LM, Zhang LQ, Zhang L, Zhang P, Zhang QY, Zhang S, Zhang S, Zhang XD, Zhang XM, Zhang XY, Zhang XY, Zhang Y, Zhang YT, Zhang YH, Zhang Y, Zhang Y, Zhang ZH, Zhang ZY, Zhang ZY, Zhao G, Zhao J, Zhao JY, Zhao JZ, Zhao L, Zhao L, Zhao MG, Zhao Q, Zhao SJ, Zhao YB, Zhao YX, Zhao ZG, Zhemchugov A, Zheng B, Zheng JP, Zheng YH, Zhong B, Zhong C, Zhong X, Zhou H, Zhou LP, Zhou X, Zhou XK, Zhou XR, Zhou XY, Zhou YZ, Zhu J, Zhu K, Zhu KJ, Zhu LX, Zhu SH, Zhu SQ, Zhu TJ, Zhu WJ, Zhu YC, Zhu ZA, Zou BS, Zou JH. Measurement of the Absolute Branching Fraction and Decay Asymmetry of Λ→nγ. PHYSICAL REVIEW LETTERS 2022; 129:212002. [PMID: 36461970 DOI: 10.1103/physrevlett.129.212002] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/23/2022] [Revised: 09/27/2022] [Accepted: 10/24/2022] [Indexed: 06/17/2023]
Abstract
The radiative hyperon decay Λ→nγ is studied using (10087±44)×10^{6} J/ψ events collected with the BESIII detector operating at BEPCII. The absolute branching fraction of the decay Λ→nγ is determined to be (0.832±0.038_{stat}±0.054_{syst})×10^{-3}, which is a factor of 2.1 lower and 5.6 standard deviations different than the previous measurement. By analyzing the joint angular distribution of the decay products, the first determination of the decay asymmetry α_{γ} is reported with a value of -0.16±0.10_{stat}±0.05_{syst}.
Collapse
|
216
|
Pan BJ, Gong QX, Li H, Ma SY, Song GX, Li X, Ding Y, Fan QH, Zhang ZH. [CIC-rearranged sarcoma with rhabdoid features: a clinicopathological analysis]. ZHONGHUA BING LI XUE ZA ZHI = CHINESE JOURNAL OF PATHOLOGY 2022; 51:1141-1146. [PMID: 36323544 DOI: 10.3760/cma.j.cn112151-20220831-00752] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/16/2023]
Abstract
Objective: To investigate the histopathologic, immunohistochemical, molecular genetic characteristics of CIC-rearranged sarcoma (CRS) with rhabdoid features. Methods: The clinical and pathologic data of two cases of CRS diagnosed between 2019 and 2021 at the Department of Pathology, Jiangsu Province Hospital were analyzed. Immunohistochemical study and fluorescence in situ hybridization (FISH) were performed. The relevant literature was reviewed. Results: Both patients were female, one was 58 years old, with tumor located in left thigh; the other was 43 years old, with tumor located in left pelvic cavity. Microscopically, both tumors were composed of small to medium-sized round, oval cells, arranged in nodules or sheets. The tumor cells showed irregular nuclear outline, coarse chromatin with prominent nucleoli and brisk mitotic activity. Both cases showed rhabdoid phenotype with myxoid stromal changes. Immunohistochemically, both cases were positive for CD99 and c-myc. High WT1 reactivity was seen in classic area, with low reactivity in rhabdoid area. There was no INI1 lost in both cases. Both were negative for NKX2.2 and NKX3.1. By FISH both cases demonstrated convincing break-apart signals of CIC gene. One patient died of disease after 1 month, and the other died of disease after 3 months. Conclusions: CRS is a small round cell undifferentiated sarcoma of the bone and soft tissue defined by molecular genetic characteristics, and may show atypical morphologic and immunophenotypic characteristics such as rhabdoid features. A correct understanding of its rare morphologic and immunophenotypic characteristics, combined with molecular pathologic detection, is conducive to correct diagnosis.
Collapse
|
217
|
Zhao AL, Tang WJ, Li Y, Liao Y, Li H, Wang J, Shen K, Yang YF, Xu J, Zhang L, Zheng YH, Niu T. [Efficacy and safety of daratumumab in patients with relapsed/refractory multiple myeloma]. ZHONGHUA YI XUE ZA ZHI 2022; 102:3304-3311. [PMID: 36319183 DOI: 10.3760/cma.j.cn112137-20220311-00498] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/16/2023]
Abstract
Objective: To investigate the efficacy and safety of daratumumab in relapsed/refractory multiple myeloma (RRMM) patients. Methods: Fifty-two RRMM patients treated with daratumumab from September 2019 to November 2021 in West China Hospital were retrospectively enrolled, including 31 males and 21 females. The mean age of these patients at the first diagnosis of multiple myeloma was (58±10) years. According to the dosage of daratumumab, patients were divided into low dosage group (n=10) and high dosage group (n=42). Overall response rate (ORR), progression-free survival (PFS), overall survival (OS), and adverse event rates were investigated. Univariate and multivariate analysis of potential factors were conducted. Results: Of the 52 patients, 8 received daratumumab monotherapy, 27 received daratumumab plus immuno-modulatory drug (IMiD) treatment, 4 received daratumumab plus proteosome inhibitor (PI) treatment, and 11 received daratumumab plus dexamethasone treatment. The diagnosis age of high dosage group patients was (57±9) years, which was significantly younger than that of low dosage group [(66±10) years] (P=0.009). The baseline creatinine level of high dosage group patients [M (Q1, Q3)] was 91 (68, 196) μmol/L, which was significantly higher than that of low dosage group [66 (51, 76) μmol/L] (P=0.021). There was no significant difference in other baseline clinical characteristics, previous treatment regimens, previous lines of treatment, and regimen and cycles of daratumumab between the high dosage group and low dosage group (all P>0.05). The ORR for the 52 patients was 71.2% (37/52). The ORR for daratumumab plus IMiD group was 81.5% (22/27), which was significantly higher than that in monotherapy or dexamethasone group [ORR: 52.6% (10/19), P=0.036). With a median follow-up [M (Q1, Q3)] of 7 (5, 26) months, the median PFS for overall cohort was 17 (95%CI: 9.6-24.4) months. The median PFS for daratumumab plus IMiD group was 26 (95%CI: 6.0-46.0) months, which was significantly better than that in monotherapy or dexamethasone group [12 (95%CI: 3.5-20.5) months] (HR=0.231, 95%CI: 0.075-0.715, P=0.011). Higher diagnosis age was the risk factor of progression (HR=1.085, 95%CI: 1.016-1.158, P=0.014), while more cycles of daratumumab treatment was the protective factor of progression (HR=0.669, 95%CI: 0.495-0.904, P=0.009). There was no significant influence of daratumumab dosage on progression (high dosage vs low dosage, HR=1.016, 95%CI: 0.221-4.668, P=0.984). The median OS for overall cohort was 26 (95%CI: 13.1-38.9) months. Higher serum calcium was the independent risk factor of death (HR=12.190, 95%CI: 1.170-127.048, P=0.037). There was no significant influence of daratumumab dosage on death (high dosage vs low dosage, HR=0.818, 95%CI: 0.171-3.917, P=0.802). Adverse events included infections (43.2%, 16/37), infusion-associated reactions (29.7%, 11/37), and thrombocytopenia (27.0%, 10/37). Conclusions: Daratumumab is effective to treat RRMM. The dosage of daratumumab has no significant influence on prognosis when used in combined treatment. The incidence of adverse events is relatively low, with a favorable safety profile.
Collapse
|
218
|
Ablikim M, Achasov MN, Adlarson P, Ahmed S, Albrecht M, Aliberti R, Amoroso A, An MR, An Q, Bai XH, Bai Y, Bakina O, Ferroli RB, Balossino I, Ban Y, Batozskaya V, Becker D, Begzsuren K, Berger N, Bertani M, Bettoni D, Bianchi F, Bloms J, Bortone A, Boyko I, Briere RA, Cai H, Cai X, Calcaterra A, Cao GF, Cao N, Cetin SA, Chang JF, Chang WL, Chelkov G, Chen C, Chen G, Chen HS, Chen ML, Chen SJ, Chen T, Chen XR, Chen XT, Chen YB, Chen ZJ, Cheng WS, Cibinetto G, Cossio F, Cui JJ, Cui XF, Dai HL, Dai JP, Dai XC, Dbeyssi A, de Boer RE, Dedovich D, Deng ZY, Denig A, Denysenko I, Destefanis M, De Mori F, Ding Y, Dong C, Dong J, Dong LY, Dong MY, Dong X, Du SX, Egorov P, Fan YL, Fang J, Fang SS, Fang Y, Farinelli R, Fava L, Feldbauer F, Felici G, Feng CQ, Feng JH, Fritsch M, Fu CD, Gao Y, Gao Y, Garzia I, Ge PT, Geng C, Gersabeck EM, Gilman A, Goetzen K, Gong L, Gong WX, Gradl W, Greco M, Gu MH, Gu YT, Guan CY, Guo AQ, Guo AQ, Guo LB, Guo RP, Guo YP, Guskov A, Han TT, Han WY, Hao XQ, Harris FA, He KK, He KL, Heinsius FH, Heinz CH, Heng YK, Herold C, Himmelreich M, Holtmann T, Hou GY, Hou YR, Hou ZL, Hu HM, Hu JF, Hu T, Hu Y, Huang GS, Huang LQ, Huang XT, Huang YP, Huang Z, Hussain T, Hüsken N, Andersson WI, Imoehl W, Irshad M, Jaeger S, Janchiv S, Ji Q, Ji QP, Ji XB, Ji XL, Ji YY, Jiang HB, Jiang SS, Jiang XS, Jiao JB, Jiao Z, Jin S, Jin Y, Jing MQ, Johansson T, Kalantar-Nayestanaki N, Kang XS, Kappert R, Kavatsyuk M, Ke BC, Keshk IK, Khoukaz A, Kiese P, Kiuchi R, Kliemt R, Koch L, Kolcu OB, Kopf B, Kuemmel M, Kuessner M, Kupsc A, Kurth MG, Kühn W, Lane JJ, Lange JS, Larin P, Lavania A, Lavezzi L, Lei ZH, Leithoff H, Lellmann M, Lenz T, Li C, Li C, Li CH, Li C, Li DM, Li F, Li G, Li H, Li H, Li HB, Li HJ, Li HN, Li JL, Li JQ, Li JS, Li K, Li LJ, Li LK, Li L, Li MH, Li PR, Li SY, Li T, Li WD, Li WG, Li XH, Li XL, Li X, Li ZY, Liang H, Liang H, Liang H, Liang YF, Liang YT, Liao GR, Liao LZ, Libby J, Limphirat A, Lin CX, Lin DX, Lin T, Liu BJ, Liu CX, Liu D, Liu FH, Liu F, Liu F, Liu GM, Liu HB, Liu HM, Liu H, Liu H, Liu JB, Liu JL, Liu JY, Liu K, Liu KY, Liu K, Liu L, Liu MH, Liu PL, Liu Q, Liu SB, Liu T, Liu T, Liu WM, Liu X, Liu Y, Liu YB, Liu ZA, Liu ZQ, Lou XC, Lu FX, Lu HJ, Lu JD, Lu JG, Lu XL, Lu Y, Lu YP, Lu ZH, Luo CL, Luo MX, Luo T, Luo XL, Lyu XR, Lyu YF, Ma FC, Ma HL, Ma LL, Ma MM, Ma QM, Ma RQ, Ma RT, Ma XX, Ma XY, Ma Y, Maas FE, Maggiora M, Maldaner S, Malde S, Malik QA, Mangoni A, Mao YJ, Mao ZP, Marcello S, Meng ZX, Messchendorp JG, Mezzadri G, Miao H, Min TJ, Mitchell RE, Mo XH, Muchnoi NY, Muramatsu H, Nakhoul S, Nefedov Y, Nerling F, Nikolaev IB, Ning Z, Nisar S, Olsen SL, Ouyang Q, Pacetti S, Pan X, Pan Y, Pathak A, Pathak A, Patteri P, Pelizaeus M, Peng HP, Peters K, Pettersson J, Ping JL, Ping RG, Plura S, Pogodin S, Poling R, Prasad V, Qi H, Qi HR, Qi M, Qi TY, Qian S, Qian WB, Qian Z, Qiao CF, Qin JJ, Qin LQ, Qin XP, Qin XS, Qin ZH, Qiu JF, Qu SQ, Rashid KH, Ravindran K, Redmer CF, Ren KJ, Rivetti A, Rodin V, Rolo M, Rong G, Rosner C, Rump M, Sang HS, Sarantsev A, Schelhaas Y, Schnier C, Schoenning K, Scodeggio M, Shan W, Shan XY, Shangguan JF, Shao LG, Shao M, Shen CP, Shen HF, Shen XY, Shi BA, Shi HC, Shi RS, Shi X, Shi XD, Song JJ, Song WM, Song YX, Sosio S, Spataro S, Stieler F, Su KX, Su PP, Su YJ, Sun GX, Sun HK, Sun JF, Sun L, Sun SS, Sun T, Sun WY, Sun X, Sun YJ, Sun YZ, Sun ZT, Tan YH, Tan YX, Tang CJ, Tang GY, Tang J, Tao QT, Teng JX, Thoren V, Tian WH, Tian YT, Uman I, Wang B, Wang DY, Wang HJ, Wang HP, Wang K, Wang LL, Wang M, Wang MZ, Wang M, Wang S, Wang TJ, Wang W, Wang WH, Wang WP, Wang X, Wang XF, Wang XL, Wang Y, Wang YD, Wang YF, Wang YQ, Wang YY, Wang Z, Wang ZY, Wang Z, Wang Z, Wei DH, Weidner F, Wen SP, White DJ, Wiedner U, Wilkinson G, Wolke M, Wollenberg L, Wu JF, Wu LH, Wu LJ, Wu X, Wu XH, Wu Z, Xia L, Xiang T, Xiao H, Xiao SY, Xiao ZJ, Xie XH, Xie YG, Xie YH, Xing TY, Xu CF, Xu CJ, Xu GF, Xu QJ, Xu W, Xu XP, Xu YC, Yan F, Yan L, Yan WB, Yan WC, Yang HJ, Yang HX, Yang L, Yang SL, Yang YX, Yang YX, Yang Y, Yang Z, Ye M, Ye MH, Yin JH, You ZY, Yu BX, Yu CX, Yu G, Yu JS, Yu T, Yuan CZ, Yuan L, Yuan SC, Yuan Y, Yuan ZY, Yue CX, Zafar AA, Zeng XZ, Zeng Y, Zhang AQ, Zhang BL, Zhang BX, Zhang GY, Zhang H, Zhang HH, Zhang HH, Zhang HY, Zhang JL, Zhang JQ, Zhang JW, Zhang JY, Zhang JZ, Zhang J, Zhang J, Zhang LM, Zhang LQ, Zhang L, Zhang P, Zhang S, Zhang XD, Zhang XM, Zhang XY, Zhang XY, Zhang Y, Zhang YT, Zhang YH, Zhang Y, Zhang Y, Zhang ZH, Zhang ZY, Zhang ZY, Zhao G, Zhao J, Zhao JY, Zhao JZ, Zhao L, Zhao L, Zhao MG, Zhao Q, Zhao SJ, Zhao YB, Zhao YX, Zhao ZG, Zhemchugov A, Zheng B, Zheng JP, Zheng YH, Zhong B, Zhong C, Zhou LP, Zhou Q, Zhou X, Zhou XK, Zhou XR, Zhou XY, Zhu AN, Zhu J, Zhu K, Zhu KJ, Zhu SH, Zhu TJ, Zhu WJ, Zhu WJ, Zhu YC, Zhu ZA, Zou BS, Zou JH. Observation of an Isoscalar Resonance with Exotic J^{PC}=1^{-+} Quantum Numbers in J/ψ→γηη^{'}. PHYSICAL REVIEW LETTERS 2022; 129:192002. [PMID: 36399732 DOI: 10.1103/physrevlett.129.192002] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/03/2022] [Revised: 05/03/2022] [Accepted: 09/27/2022] [Indexed: 06/16/2023]
Abstract
Using a sample of (10.09±0.04)×10^{9} J/ψ events collected with the BESIII detector operating at the BEPCII storage ring, a partial wave analysis of the decay J/ψ→γηη^{'} is performed. The first observation of an isoscalar state with exotic quantum numbers J^{PC}=1^{-+}, denoted as η_{1}(1855), is reported in the process J/ψ→γη_{1}(1855) with η_{1}(1855)→ηη^{'}. Its mass and width are measured to be (1855±9_{-1}^{+6}) MeV/c^{2} and (188±18_{-8}^{+3}) MeV, respectively, where the first uncertainties are statistical and the second are systematic, and its statistical significance is estimated to be larger than 19σ.
Collapse
|
219
|
Spetz M, Lundberg L, Nwaru C, Li H, Santosa A, Ng N, Leach S, Gisslén M, Hammar N, Nyberg F, Rosvall M. An intersectional analysis of sociodemographic disparities in Covid-19 vaccination: A nationwide register-based study in Sweden. Vaccine 2022; 40:6640-6648. [PMID: 36210254 PMCID: PMC9515344 DOI: 10.1016/j.vaccine.2022.09.065] [Citation(s) in RCA: 12] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2022] [Revised: 09/19/2022] [Accepted: 09/21/2022] [Indexed: 01/27/2023]
Abstract
BACKGROUND Studies on sociodemographic disparities in Covid-19 vaccination uptake in the general population are still limited and mostly focused on older adults. This study examined sociodemographic differences in Covid-19 vaccination uptake in the total Swedish population aged 18-64 years. METHODS National Swedish register data within the SCIFI-PEARL project were used to cross-sectionally investigate sociodemographic differences in Covid-19 vaccination among Swedish adults aged 18-64 years (n = 5,987,189) by 12 October 2021. Using logistic regression models, analyses were adjusted for sociodemographic factors, region of residence, history of Covid-19, and comorbidities. An intersectional analysis approach including several cross-classified subgroups was used to further address the complexity of sociodemographic disparities in vaccination uptake. FINDINGS By 12 October 2021, 76·0% of the Swedish population 18-64 years old had received at least two doses of Covid-19 vaccine, an additional 5·5% had received only one dose, and 18·5% were non-vaccinated. Non-vaccinated individuals were, compared to vaccinated, more often younger, male, had a lower income, were not gainfully employed, and/or were born outside Sweden. The social patterning for vaccine dose two was similar, but weaker, than for dose one. After multivariable adjustments, findings remained but were attenuated indicating the need to consider different sociodemographic factors simultaneously. The intersectional analysis showed a large variation in vaccine uptake ranging from 32% to 96% in cross-classified subgroups, reflecting considerable sociodemographic heterogeneity in vaccination coverage. INTERPRETATION Our study, addressing the entire Swedish population aged 18-64 years, showed broad sociodemographic disparities in Covid-19 vaccine uptake but also wide heterogeneities in coverage. The intersectional analysis approach indicates that focusing on specific sociodemographic factors in isolation and group average risks without considering the heterogeneity within such groups will risk missing the full variability of vaccine coverage. FUNDING SciLifeLab / Knut & Alice Wallenberg Foundation, Swedish Research Council, Swedish government ALF agreement, FORMAS.
Collapse
|
220
|
Gao F, Hu Y, Li X, Li H, Wang S, Zeng Z, Qin H. 412P Substance-P in the blood is related with the efficacy of aprepitant for targeted drug-induced refractory pruritus in Chinese malignancy population. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.10.443] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/07/2022] Open
|
221
|
Li H, Lin Y, Yu T, Xie Y, Jiang C, Feng J, Qian X, Yin Z. 346P The safety and efficacy of intrathecal chemotherapy with pemetrexed via the Ommaya reservoir for leptomeningeal metastases from lung adenocarcinoma: A prospective study. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.10.384] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/05/2022] Open
|
222
|
Lumry W, Li H, Milligan S, Raasch J, Riedl M. ATTACK LOCATION AND SEVERITY/RESOLUTION IN PATIENTS WITH HEREDITARY ANGIOEDEMA (HAE); OBSERVATIONS FROM COMMUNITY IMMUNOLOGY. Ann Allergy Asthma Immunol 2022. [DOI: 10.1016/j.anai.2022.08.593] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
223
|
Lo W, Li H, Prusator M, Maraghechi B, Michalski J, Perkins S, Yang J. Incidence of Radiation Pneumonitis after a Single 550 cGy Fraction of Total Body Irradiation: Single Institutional Experience. Int J Radiat Oncol Biol Phys 2022. [DOI: 10.1016/j.ijrobp.2022.07.1469] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
|
224
|
Shao Z, Huang T, Fan Z, Wang Y, Yan X, Yang H, Wang S, Pang D, Li H, Wang H, Geng C, Huang L, Siddiqui A, Wang B, Xie B, Sun G, Restuccia E. 1MO The fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) in Chinese patients (pts) with HER2-positive early breast cancer (EBC): Primary analysis of the phase III, randomised FDChina study. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.10.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/07/2022] Open
|
225
|
Cao Y, Chen H, Gogineni E, Li H, Deville C. Initial Experience with Real-Time Gated Proton Therapy (RGPT) in the Definitive Treatment of Prostate Cancer. Int J Radiat Oncol Biol Phys 2022. [DOI: 10.1016/j.ijrobp.2022.07.2159] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
226
|
DePaoli B, McVorran S, Case M, Khaleghi S, Li H, Marshall D. Toxicity Outcomes at 18 Months for Cs-131 Low-Dose-Rate Prostate Brachytherapy Compared to I-125 and Pd-103. Int J Radiat Oncol Biol Phys 2022. [DOI: 10.1016/j.ijrobp.2022.07.1161] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
|
227
|
Liu M, Gao X, Li H, Li X, Ma M, Xie M, Lyu F, Chen J, Ren X, Gao Y. Radiotherapy for Advanced Upper Tract Urothelial Carcinoma Intolerant to Chemotherapy. Int J Radiat Oncol Biol Phys 2022. [DOI: 10.1016/j.ijrobp.2022.07.1137] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
|
228
|
Lumry W, Jacobs J, Li H, Milligan S, O'Connor M, Raasch J, Riedl M. DEVELOPMENT OF THE PATIENT-IMPORTANT OUTCOMES NATIONAL DATA REPOSITORY (PIONEER) FOR HEREDITARY ANGIOEDEMA (HAE). Ann Allergy Asthma Immunol 2022. [DOI: 10.1016/j.anai.2022.08.591] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
229
|
Li H, Liu Y, Wang X, Chen Z, Wang J, Sun T, Li Q, Cheng J, Zhang Q, Wang X, Wang J, Gu K, Wei S, Zhang S, Wang X, Sun P, Hao C, Han C, Li Y, Kang X. Efficacy and safety of the biosimilar QL1206 compared with denosumab in breast cancer with bone metastases: subgroup analyses of a phase III study. Eur J Cancer 2022. [DOI: 10.1016/s0959-8049(22)01531-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
230
|
Ablikim M, Achasov MN, Adlarson P, Albrecht M, Aliberti R, Amoroso A, An MR, An Q, Bai XH, Bai Y, Bakina O, Ferroli RB, Balossino I, Ban Y, Batozskaya V, Becker D, Begzsuren K, Berger N, Bertani M, Bettoni D, Bianchi F, Bloms J, Bortone A, Boyko I, Briere RA, Brueggemann A, Cai H, Cai X, Calcaterra A, Cao GF, Cao N, Cetin SA, Chang JF, Chang WL, Chelkov G, Chen C, Chen G, Chen HS, Chen ML, Chen SJ, Chen T, Chen XR, Chen XT, Chen YB, Chen ZJ, Cheng WS, Cibinetto G, Cossio F, Cui JJ, Dai HL, Dai JP, Dbeyssi A, de Boer RE, Dedovich D, Deng ZY, Denig A, Denysenko I, Destefanis M, De Mori F, Ding Y, Dong J, Dong LY, Dong MY, Dong X, Du SX, Egorov P, Fan YL, Fang J, Fang SS, Fang Y, Farinelli R, Fava L, Feldbauer F, Felici G, Feng CQ, Feng JH, Fischer K, Fritsch M, Fritzsch C, Fu CD, Gao H, Gao YN, Gao Y, Garbolino S, Garzia I, Ge PT, Ge ZW, Geng C, Gersabeck EM, Gilman A, Gong L, Gong WX, Gradl W, Greco M, Gu LM, Gu MH, Gu YT, Guan CY, Guo AQ, Guo LB, Guo RP, Guo YP, Guskov A, Han TT, Han WY, Hao XQ, Harris FA, He KK, He KL, Heinsius FH, Heinz CH, Heng YK, Herold C, Holtmann T, Hou GY, Hou YR, Hou ZL, Hu HM, Hu JF, Hu T, Hu Y, Huang GS, Huang KX, Huang LQ, Huang LQ, Huang XT, Huang YP, Huang Z, Hussain T, Hüsken N, Imoehl W, Irshad M, Jackson J, Jaeger S, Janchiv S, Ji Q, Ji QP, Ji XB, Ji XL, Ji YY, Jia ZK, Jiang HB, Jiang SS, Jiang XS, Jiang Y, Jiao JB, Jiao Z, Jin S, Jin Y, Jing MQ, Johansson T, Kalantar-Nayestanaki N, Kang XS, Kappert R, Kavatsyuk M, Ke BC, Keshk IK, Khoukaz A, Kiese P, Kiuchi R, Koch L, Kolcu OB, Kopf B, Kuemmel M, Kuessner M, Kupsc A, Kühn W, Lane JJ, Lange JS, Larin P, Lavania A, Lavezzi L, Lei ZH, Leithoff H, Lellmann M, Lenz T, Li C, Li C, Li CH, Li C, Li DM, Li F, Li G, Li H, Li H, Li HB, Li HJ, Li HN, Li JQ, Li JS, Li JW, Li K, Li LJ, Li LK, Li L, Li MH, Li PR, Li SX, Li SY, Li T, Li WD, Li WG, Li XH, Li XL, Li X, Liang H, Liang H, Liang H, Liang YF, Liang YT, Liao GR, Liao LZ, Libby J, Limphirat A, Lin CX, Lin DX, Lin T, Liu BJ, Liu CX, Liu D, Liu FH, Liu F, Liu F, Liu GM, Liu H, Liu HB, Liu HM, Liu H, Liu H, Liu JB, Liu JL, Liu JY, Liu K, Liu KY, Liu K, Liu L, Liu MH, Liu PL, Liu Q, Liu SB, Liu T, Liu WK, Liu WM, Liu X, Liu Y, Liu YB, Liu ZA, Liu ZQ, Lou XC, Lu FX, Lu HJ, Lu JG, Lu XL, Lu Y, Lu YP, Lu ZH, Luo CL, Luo MX, Luo T, Luo XL, Lyu XR, Lyu YF, Ma FC, Ma HL, Ma LL, Ma MM, Ma QM, Ma RQ, Ma RT, Ma XY, Ma Y, Maas FE, Maggiora M, Maldaner S, Malde S, Malik QA, Mangoni A, Mao YJ, Mao ZP, Marcello S, Meng ZX, Messchendorp JG, Mezzadri G, Miao H, Min TJ, Mitchell RE, Mo XH, Muchnoi NY, Muramatsu H, Nefedov Y, Nerling F, Nikolaev IB, Ning Z, Nisar S, Niu Y, Olsen SL, Ouyang Q, Pacetti S, Pan X, Pan Y, Pathak A, Pathak A, Pelizaeus M, Peng HP, Pettersson J, Ping JL, Ping RG, Plura S, Pogodin S, Poling R, Prasad V, Qi H, Qi HR, Qi M, Qi TY, Qian S, Qian WB, Qian Z, Qiao CF, Qin JJ, Qin LQ, Qin XP, Qin XS, Qin ZH, Qiu JF, Qu SQ, Qu SQ, Rashid KH, Redmer CF, Ren KJ, Rivetti A, Rodin V, Rolo M, Rong G, Rosner C, Ruan SN, Sang HS, Sarantsev A, Schelhaas Y, Schnier C, Schoenning K, Scodeggio M, Shan KY, Shan W, Shan XY, Shangguan JF, Shao LG, Shao M, Shen CP, Shen HF, Shen XY, Shi BA, Shi HC, Shi RS, Shi X, Shi XD, Song JJ, Song WM, Song YX, Sosio S, Spataro S, Stieler F, Su KX, Su PP, Su YJ, Sun GX, Sun H, Sun HK, Sun JF, Sun L, Sun SS, Sun T, Sun WY, Sun X, Sun YJ, Sun YZ, Sun ZT, Tan YH, Tan YX, Tang CJ, Tang GY, Tang J, Tao LY, Tao QT, Teng JX, Thoren V, Tian WH, Tian Y, Uman I, Wang B, Wang BL, Wang CW, Wang DY, Wang F, Wang HJ, Wang HP, Wang K, Wang LL, Wang M, Wang MZ, Wang M, Wang S, Wang T, Wang TJ, Wang W, Wang WH, Wang WP, Wang X, Wang XF, Wang XL, Wang YD, Wang YF, Wang YH, Wang YQ, Wang Z, Wang ZY, Wang Z, Wei DH, Weidner F, Wen SP, White DJ, Wiedner U, Wilkinson G, Wolke M, Wollenberg L, Wu JF, Wu LH, Wu LJ, Wu X, Wu XH, Wu Y, Wu Z, Xia L, Xiang T, Xiao D, Xiao GY, Xiao H, Xiao SY, Xiao YL, Xiao ZJ, Xie C, Xie XH, Xie Y, Xie YG, Xie YH, Xie ZP, Xing TY, Xu CF, Xu CJ, Xu GF, Xu HY, Xu QJ, Xu SY, Xu XP, Xu YC, Xu ZP, Yan F, Yan L, Yan WB, Yan WC, Yang HJ, Yang HL, Yang HX, Yang L, Yang SL, Yang YX, Yang Y, Ye M, Ye MH, Yin JH, You ZY, Yu BX, Yu CX, Yu G, Yu T, Yuan CZ, Yuan L, Yuan SC, Yuan XQ, Yuan Y, Yuan ZY, Yue CX, Zafar AA, Zeng FR, Zeng X, Zeng Y, Zhan YH, Zhang AQ, Zhang BL, Zhang BX, Zhang GY, Zhang H, Zhang HH, Zhang HH, Zhang HY, Zhang JL, Zhang JQ, Zhang JW, Zhang JX, Zhang JY, Zhang JZ, Zhang J, Zhang J, Zhang LM, Zhang LQ, Zhang L, Zhang P, Zhang QY, Zhang S, Zhang XD, Zhang XM, Zhang XY, Zhang XY, Zhang Y, Zhang YT, Zhang YH, Zhang Y, Zhang Y, Zhang ZH, Zhang ZY, Zhang ZY, Zhao G, Zhao J, Zhao JY, Zhao JZ, Zhao L, Zhao L, Zhao MG, Zhao Q, Zhao SJ, Zhao YB, Zhao YX, Zhao ZG, Zhemchugov A, Zheng B, Zheng JP, Zheng YH, Zhong B, Zhong C, Zhong X, Zhou H, Zhou LP, Zhou X, Zhou XK, Zhou XR, Zhou XY, Zhou YZ, Zhu J, Zhu K, Zhu KJ, Zhu LX, Zhu SH, Zhu SQ, Zhu TJ, Zhu WJ, Zhu YC, Zhu ZA, Zou BS, Zou JH. Observation of an a_{0}-like State with Mass of 1.817 GeV in the Study of D_{s}^{+}→K_{S}^{0}K^{+}π^{0} Decays. PHYSICAL REVIEW LETTERS 2022; 129:182001. [PMID: 36374689 DOI: 10.1103/physrevlett.129.182001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/24/2022] [Revised: 07/08/2022] [Accepted: 09/13/2022] [Indexed: 06/16/2023]
Abstract
Using e^{+}e^{-} annihilation data corresponding to an integrated luminosity of 6.32 fb^{-1} collected at center-of-mass energies between 4.178 and 4.226 GeV with the BESIII detector, we perform the first amplitude analysis of the decay D_{s}^{+}→K_{S}^{0}K^{+}π^{0} and determine the relative branching fractions and phases for intermediate processes. We observe an a_{0}-like state with mass of 1.817 GeV in its decay to K_{S}^{0}K^{+} for the first time. In addition, we measure the ratio {B[D_{s}^{+}→K[over ¯]^{*}(892)^{0}K^{+}]/B[D_{s}^{+}→K[over ¯]^{0}K^{*}(892)^{+}]} to be 2.35_{-0.23stat}^{+0.42}±0.10_{syst}. Finally, we provide a precision measurement of the absolute branching fraction B(D_{s}^{+}→K_{S}^{0}K^{+}π^{0})=(1.46±0.06_{stat}±0.05_{syst})%.
Collapse
|
231
|
Nwaru C, Li H, Bonander C, Santosa A, Franzén S, Rosvall M, Nyberg F. Occupational role and Covid-19 among foreign-born healthcare workers: a registry-based study. Eur J Public Health 2022. [DOI: 10.1093/eurpub/ckac130.175] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Studies have shown an elevated risk of Covid-19 among foreign-born healthcare workers (HCWs), but data on the distribution of the risk in different occupational roles are lacking. Such data are needed for the effective control of Covid-19 risk among HCWs. Here, we examined the risk of Covid-19 infection and hospitalization in foreign-born HCWs in different occupational roles in Sweden.
Methods
We prospectively linked occupational data (2018-2019) of 783950 employed foreign-born (20-65 years) workers to Covid-19 data registered between 1 January 2020 and 30 September 2021. We used Cox proportional hazards regression to estimate the risk of Covid-19 infection and hospitalization in foreign-born HCWs in eight different occupational groups compared to non-HCWs, and to assess whether the associations varied by region of birth. The analyses were adjusted for sociodemographic and socioeconomic factors, comorbidities, and Covid-19 vaccination.
Results
All HCWs had a higher risk of Covid-19 outcomes than non-HCWs, but the risk differed by occupational role. Assistant nurses had the highest risk both for Covid-19 infection (HR 1.80; 95%CI 1.74-1.87) and hospitalization (HR 1.85; 95%CI 1.57-2.18); other allied HCWs had the lowest risk (infection: HR 1.23; 95%CI 1.11-1.36; hospitalization: HR 1.02; 95%CI 0.63-1.67)). In some healthcare occupations, the relative risk of Covid-19 varied by region of birth. For example, physicians and dental nurses/hygienists of African and Asian origin had a higher risk of Covid-19 infection than European-born in the same occupation. In contrast, European-born assistant nurses had a greater risk of both outcomes than non-European-born in the same occupation.
Conclusions
The risk of Covid-19 among foreign-born HCWs varied by occupational role and region of birth. Public health efforts that target occupational exposures as well as incorporate culturally responsive measures may help to reduce Covid-19 risk among foreign-born HCWs.
Key messages
Collapse
|
232
|
Emmanuel N, Li H, Chen J, Zhang Y. FSP1, a novel KEAP1/NRF2 target gene regulating ferroptosis and radioresistance in lung cancers. Oncotarget 2022; 13:1136-1139. [PMID: 36264074 PMCID: PMC9584440 DOI: 10.18632/oncotarget.28301] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023] Open
Abstract
In the study of "A targetable CoQ-FSP1 axis drives ferroptosis- and radiation-resistance in KEAP1 inactive lung cancers" which was published earlier in Nature Communications, the authors have identified a novel KEAP1/NRF2 target gene, FSP1, and demonstrated that FSP1 plays an essential role in NRF2-mediated ferroptosis resistance and radioresistance in KEAP1-deficient lung cancer cells. Currently, many NRF2 target genes have been found to participate in the regulation of ferroptosis, and exactly which one plays a dominant role seems unclear. This study proposes that FSP1 is the key effector in NRF2-mediated ferroptosis resistance and radioresistance in KEAP-deficient lung cancer cells, as we discussed in the manuscript.
Collapse
|
233
|
Bai X, Niu J, Li H, Miao Y, Zhang F. Gastrointestinal: Tuberculosis with anal fistula and multisegmental damage in the digestive tract involving the stomach, ileocecum, and colon. J Gastroenterol Hepatol 2022; 38:484. [PMID: 36250909 DOI: 10.1111/jgh.15991] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/08/2022] [Revised: 06/29/2022] [Accepted: 08/30/2022] [Indexed: 12/09/2022]
|
234
|
Fan SQ, Yan SQ, Zhu XZ, Li J, Tong CG, Li H, Cao XY, Wu LL, Xie ZL, Wei FB, Tao F. [Independent and combined effects of pre-pregnancy BMI and gestational diabetes on early adiposity rebound timing in children]. ZHONGHUA LIU XING BING XUE ZA ZHI = ZHONGHUA LIUXINGBINGXUE ZAZHI 2022; 43:1626-1631. [PMID: 36456495 DOI: 10.3760/cma.j.cn112338-20220429-00364] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/17/2023]
Abstract
Objective: To examine the independent and combined effects of pre-pregnancy BMI and gestational diabetes (GDM) on early adiposity rebound (AR) timing in children. Methods: Based on the "Ma'anshan Birth Cohort Study", 2 896 eligible maternal and infant pairs were recruited. In the cohort, we collected pre-pregnancy height, weight, 24 to 28 weeks GDM diagnosis, follow-up at 42 days, three months, six months, nine months of age, and every six months after one year of age, and continuously followed up to 6 years old, and obtained the child's length/height, weight, and other data. The intensity of the association between pre-pregnancy BMI, GDM, and early AR timing was analyzed by the multivariate logistic regression model. Multiplication and additive models were used to analyze how pre-pregnancy BMI and GDM influenced early AR timing in children. Results: The prevalence of underweight, average weight, overweight, and obesity before pregnancy were 23.2% (672), 66.4% (1 923), 8.7% (251), and 1.7% (50). The prevalence of GDM was 12.4%. We found that 39.3% of children had AR, and the average age at AR was (4.38±1.08). The results of multifactorial logistic regression analysis showed that pre-pregnancy overweight (OR=1.67,95%CI:1.27-2.19), pre-pregnancy obesity (OR=3.05,95%CI:1.66-5.56), and maternal GDM (OR=1.40,95%CI:1.11-1.76) were risk factors for early AR timing in children. In contrast, pre-pregnancy underweight (OR=0.60,95%CI:0.49-0.73) was a protective factor for early AR timing in children. Compared with the different effects of pre-pregnancy overweight/obesity and maternal GDM alone, the combined effect caused a higher risk of early AR timing in children, with OR values (95%CI) were 2.03 (1.20-3.44), 3.43 (1.06-11.12), respectively. The multiplication and additive models showed no interaction between pre-pregnancy BMI and GDM-influenced early AR timing in children. Conclusion: Higher pre-pregnancy BMI and maternal GDM are the independent risk factors for the early AR timing in children, and the co-occurrence of the two is higher risks, but there was no statistical interaction.
Collapse
|
235
|
Meng R, Liu SS, Fang YL, Gao R, Hou BX, Li H. [Root canal therapy of maxillary first molar with seven root canals: a case report]. ZHONGHUA KOU QIANG YI XUE ZA ZHI = ZHONGHUA KOUQIANG YIXUE ZAZHI = CHINESE JOURNAL OF STOMATOLOGY 2022; 57:1068-1071. [PMID: 36266082 DOI: 10.3760/cma.j.cn112144-20220330-00145] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/16/2023]
|
236
|
Kovács S, Li H, Bühlmann P, Munk A. Seeded Binary Segmentation: A general methodology for fast and optimal changepoint detection. Biometrika 2022. [DOI: 10.1093/biomet/asac052] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Summary
We propose seeded binary segmentation for large scale changepoint detection problems. We construct a deterministic set of background intervals, called seeded intervals, in which single changepoint candidates are searched for. The final selection of changepoints based on these candidates can be done in various ways, adapted to the problem at hand. The method is thus easy to adapt to many changepoint problems, ranging from univariate to high-dimensional. Compared to recently popular random background intervals, seeded intervals lead to reproducibility and much faster computations. For the univariate Gaussian change in mean set-up, the methodology is shown to be asymptotically minimax optimal when paired with appropriate selection criteria. We demonstrate near-linear runtimes and competitive finite sample estimation performance. Furthermore, we illustrate the versatility of our method in high-dimensional settings.
Collapse
|
237
|
Hong C, Li H, Parel PM, Berg AR, Rodante J, Keel A, Teague HL, Playford MP, Chen MY, Zhou W, Sorokin AV, Bluemke DA, Mehta NN. Application of machine learning to identify top determinants of fibrofatty plaque burden by CCTA in humans with psoriasis. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.213] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Introduction
Fibrofatty plaque burden (FFB) is a high-risk, vulnerable plaque feature comprised of an atheromatous core and fibrous cap with increased risk of coronary artery disease (CAD) [1]. Psoriasis (PSO) is a chronic inflammatory disease linked with atherosclerotic risk and premature cardiovascular disease, driven in part by vulnerable plaque rupture [2,3]. Machine learning (ML) previously showed the prognostic value of FFB in predicting 5-year risk of cardiac-related mortality in patients with CAD [4]. Whether ML can predict FFB in psoriasis is understudied.
Purpose
To use ML to identify top determinants of FFB by CCTA in PSO.
Methods
320 consecutive participants with psoriasis were recruited as part of an ongoing cohort study, of whom 307 had FFB analyzed with coronary computed tomography angiography (CCTA) and quantified by QAngio CT (Medis, The Netherlands). 140 out of 182 potential determinants were subjected to ML algorithms analyzed by random forest and validated by 5-fold cross validation to select the top determinants based on R-square criteria. Lipid concentration and size were measured by nuclear magnetic resonance (NMR) and sdLDL-C was calculated by Sampson's formula.
Results
The top 21 determinants of FFB at baseline were grouped into 3 categories: cardiometabolic risk factors (BMI, sex, DBP, mean arterial pressure, exercise, heart rate, glucose, anxiety, psoriasis disease duration), clinical measurements (basophils, platelets, hemoglobin, RBC, alkaline phosphatase, ALT, creatinine, neutrophil-to-lymphocyte ratio), and lipoproteins (LDL particle size, apolipoprotein A1, apolipoprotein B-to-A1 ratio, calculated sdLDL-C).
Conclusion
ML confirmed that FFB strongly correlates with cardiometabolic risk factors, clinical measurements, and lipoproteins. Further investigations into these top determinants of FFB over time may provide insight into potential therapeutic interventions that decrease cardiovascular risk in patients with chronic inflammatory diseases and should be validated in larger studies.
Funding Acknowledgement
Type of funding sources: Public Institution(s). Main funding source(s): This study was supported by the National Heart, Lung and Blood Institute (NHLBI) IntramuralResearch Program (ZIA-HL-06193). This research was made possible through the NIH MedicalResearch Scholars Program, a public-private partnership supported jointly by the NIH andcontributions to the Foundation for the NIH from the Doris Duke Charitable Foundation,Genentech, the American Association for Dental Research, the Colgate-Palmolive Company, andother private donors.
Collapse
|
238
|
An X, Zang M, Xiong L, Ke H, Tao Y, Chen C, Li H. HX301, a potent CSF1R inhibitor, suppresses tumor associated M2 macrophage (TAM), enhancing tumor immunity and causing transit tumor inhibition in syngeneic EMT-6 tumors. Eur J Cancer 2022. [DOI: 10.1016/s0959-8049(22)01126-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
239
|
Wu Q, Feng L, Li H, Huang S, Shi L, Li L, Li H, Zhang L, Yang F, Zhang Y, Wu Q. Post-hospitalisation respiratory and physical functions in patients with SARS-CoV-2 delta. Int J Tuberc Lung Dis 2022; 26:922-928. [PMID: 36163659 DOI: 10.5588/ijtld.21.0773] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Despite growing concern regarding the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) delta variant of concern (VOC), the respiratory and physical functions of patients with delta VOC post-discharge have not been investigated compared to those of patients with ancestral SARS-CoV-2.METHODS Sixty-three discharged patients with coronavirus disease (COVID-19) were included. Patients were divided into delta VOC and ancestral SARS-CoV-2 groups. On Day 14 post-discharge, differences in chest computed tomography, modified Medical Research Council and Borg Dyspnoea Scale scores, and Manual Muscle Test scores were compared. Prognoses of respiratory and physical function were compared between patients who recovered from moderate and severe COVID-19.RESULTS Of the 63 patients, respectively 28 and 35 were in the delta VOC and ancestral SARS-CoV-2 groups. On Day 14 post-discharge, 35 patients (56.5%) had abnormalities on imaging. Visual semi-quantitative scores of both lungs were significantly higher in the severe group. However, there was no difference in this or any other score ratings between the groups.CONCLUSION At 14 days post-discharge, ground glass opacities and pleural thickening were the most common residual findings; no difference in respiratory and physical functions during the convalescence period were noted in patients with SARS-CoV-2 delta VOC and ancestral SARS-CoV-2.
Collapse
|
240
|
Jiao Z, Ke H, Zhang F, Li H, Wang J. HX301 (ON123300) shows broad antitumor activity in preclinical mantle cell lymphoma models, inclusive of those resistant to BTKi. Eur J Cancer 2022. [DOI: 10.1016/s0959-8049(22)00850-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
241
|
Li T, Xie J, Shen C, Cheng D, Shi Y, Wu Z, Deng X, Chen H, Shen B, Peng C, Li H, Zhan Q, Zhu Z. Retraction Note: Upregulation of long noncoding RNA ZEB1-AS1 promotes tumor metastasis and predicts poor prognosis in hepatocellular carcinoma. Oncogene 2022; 41:4839. [PMID: 36180782 DOI: 10.1038/s41388-022-02480-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
242
|
Gao YJ, Shen KN, Feng J, Chang L, Li H, Su W, Cao XX, Zhang L, Zhou DB, Li J. [Prognostic value of translocation t(11;14) in primary light-chain amyloidosis treated with bortezomib-based regimen]. ZHONGHUA YI XUE ZA ZHI 2022; 102:2854-2860. [PMID: 36153870 DOI: 10.3760/cma.j.cn112137-20211227-02908] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/16/2023]
Abstract
Objective: To investigate the prognostic value of translocation t(11;14) in newly-diagnosed primary light-chain (AL) amyloidosis patients treated with bortezomib-based regimen. Method: Clinical information of newly-diagnosed AL amyloidosis patients in Peking Union Medical College Hospital who had baseline t(11;14) data and accepted bortezomib-combined therapies from September, 2015 to September, 2021 was collected. The relationships between t(11;14) status and baseline characteristics, hematological response, organ response and prognosis were analyzed. Results: A total of 152 patients were included, aged (59.5±9.1) years and 93 cases were male (61.2%). Forty-six patients carried t(11;14) (30.3%). There was no statistical difference in the proportion of organ involved, distribution of Mayo 2004 and 2012 stages and laboratory indexes between patients with and without t(11;14) (all P>0.05). For hematological response, the difference in the rates of ≥very good partial response (VGPR) between those with t(11;14) and without after the first cycle [28.2%(11/39) vs 37.4%(34/91), P>0.05] was not statistically significant. After 3 cycles, the difference in the rates of ≥VGPR between two groups was not statistically significant [35.9%(14/39) vs 51.1%(46/90), P>0.05]. The difference in the ratio of the best hematological response reaching ≥VGPR between two groups during the first-line treatment was not statistically significant [52.2%(24/46) vs 64.2%(68/106), P>0.05]. But patients with t(11;14) had lower cardiac response rate at 3 months [15.2%(5/33) vs 34.6%(28/81), P=0.038] and 6 months [19.4%(6/31) vs 50.6%(42/83),P=0.003] than those without, but the difference in cardiac response rates at 12 months was not statistically significant [41.7%(10/24) vs 53.5%(38/71),P>0.05]. For survival, the differences in overall survival (not reached vs 50.1 months, P>0.05) and hematological event-free survival (36.2 months vs 39.9 months, P>0.05) between patients carrying t(11;14) and those without were not statistically significant. Conclusion: Patients with t(11;14) had lower cardiac response rate than those without, but their hematological response and survival are not significantly different from those free from t(11;14).
Collapse
|
243
|
Ablikim M, Achasov MN, Adlarson P, Albrecht M, Aliberti R, Amoroso A, An MR, An Q, Bai XH, Bai Y, Bakina O, Baldini Ferroli R, Balossino I, Ban Y, Batozskaya V, Becker D, Begzsuren K, Berger N, Bertani M, Bettoni D, Bianchi F, Bloms J, Bortone A, Boyko I, Briere RA, Brueggemann A, Cai H, Cai X, Calcaterra A, Cao GF, Cao N, Cetin SA, Chang JF, Chang WL, Chelkov G, Chen C, Chen C, Chen G, Chen HS, Chen ML, Chen SJ, Chen SM, Chen T, Chen XR, Chen XT, Chen YB, Chen ZJ, Cheng WS, Choi SK, Chu X, Cibinetto G, Cossio F, Cui JJ, Dai HL, Dai JP, Dbeyssi A, de Boer RE, Dedovich D, Deng ZY, Denig A, Denysenko I, Destefanis M, De Mori F, Ding Y, Dong J, Dong LY, Dong MY, Dong X, Du SX, Egorov P, Fan YL, Fang J, Fang SS, Fang WX, Fang Y, Farinelli R, Fava L, Feldbauer F, Felici G, Feng CQ, Feng JH, Fischer K, Fritsch M, Fritzsch C, Fu CD, Gao H, Gao YN, Gao Y, Garbolino S, Garzia I, Ge PT, Ge ZW, Geng C, Gersabeck EM, Gilman A, Goetzen K, Gong L, Gong WX, Gradl W, Greco M, Gu LM, Gu MH, Gu YT, Guan CY, Guo AQ, Guo LB, Guo RP, Guo YP, Guskov A, Han TT, Han WY, Hao XQ, Harris FA, He KK, He KL, Heinsius FH, Heinz CH, Heng YK, Herold C, Himmelreich M, Hou GY, Hou YR, Hou ZL, Hu HM, Hu JF, Hu T, Hu Y, Huang GS, Huang KX, Huang LQ, Huang LQ, Huang XT, Huang YP, Huang Z, Hussain T, Hüsken N, Imoehl W, Irshad M, Jackson J, Jaeger S, Janchiv S, Jang E, Jeong JH, Ji Q, Ji QP, Ji XB, Ji XL, Ji YY, Jia ZK, Jiang HB, Jiang SS, Jiang XS, Jiang Y, Jiao JB, Jiao Z, Jin S, Jin Y, Jing MQ, Johansson T, Kalantar-Nayestanaki N, Kang XS, Kappert R, Ke BC, Keshk IK, Khoukaz A, Kiese P, Kiuchi R, Kliemt R, Koch L, Kolcu OB, Kopf B, Kuemmel M, Kuessner M, Kupsc A, Kühn W, Lane JJ, Lange JS, Larin P, Lavania A, Lavezzi L, Lei ZH, Leithoff H, Lellmann M, Lenz T, Li C, Li C, Li CH, Li C, Li DM, Li F, Li G, Li H, Li H, Li HB, Li HJ, Li HN, Li JQ, Li JS, Li JW, Li K, Li LJ, Li LK, Li L, Li MH, Li PR, Li SX, Li SY, Li T, Li WD, Li WG, Li XH, Li XL, Li X, Liang H, Liang H, Liang H, Liang YF, Liang YT, Liao GR, Liao LZ, Libby J, Limphirat A, Lin CX, Lin DX, Lin T, Liu BJ, Liu CX, Liu D, Liu FH, Liu F, Liu F, Liu GM, Liu H, Liu HB, Liu HM, Liu H, Liu H, Liu JB, Liu JL, Liu JY, Liu K, Liu KY, Liu K, Liu L, Liu L, Liu MH, Liu PL, Liu Q, Liu SB, Liu T, Liu WK, Liu WM, Liu X, Liu Y, Liu YB, Liu ZA, Liu ZQ, Lou XC, Lu FX, Lu HJ, Lu JG, Lu XL, Lu Y, Lu YP, Lu ZH, Luo CL, Luo MX, Luo T, Luo XL, Lyu XR, Lyu YF, Ma FC, Ma HL, Ma LL, Ma MM, Ma QM, Ma RQ, Ma RT, Ma XY, Ma Y, Maas FE, Maggiora M, Maldaner S, Malde S, Malik QA, Mangoni A, Mao YJ, Mao ZP, Marcello S, Meng ZX, Messchendorp JG, Mezzadri G, Miao H, Min TJ, Mitchell RE, Mo XH, Muchnoi NY, Nefedov Y, Nerling F, Nikolaev IB, Ning Z, Nisar S, Niu Y, Olsen SL, Ouyang Q, Pacetti S, Pan X, Pan Y, Pathak A, Pelizaeus M, Peng HP, Peters K, Ping JL, Ping RG, Plura S, Pogodin S, Prasad V, Qi FZ, Qi H, Qi HR, Qi M, Qi TY, Qian S, Qian WB, Qian Z, Qiao CF, Qin JJ, Qin LQ, Qin XP, Qin XS, Qin ZH, Qiu JF, Qu SQ, Rashid KH, Redmer CF, Ren KJ, Rivetti A, Rodin V, Rolo M, Rong G, Rosner C, Ruan SN, Sang HS, Sarantsev A, Schelhaas Y, Schnier C, Schönning K, Scodeggio M, Shan KY, Shan W, Shan XY, Shangguan JF, Shao LG, Shao M, Shen CP, Shen HF, Shen XY, Shi BA, Shi HC, Shi JY, Shi QQ, Shi RS, Shi X, Shi XD, Song JJ, Song WM, Song YX, Sosio S, Spataro S, Stieler F, Su KX, Su PP, Su YJ, Sun GX, Sun H, Sun HK, Sun JF, Sun L, Sun SS, Sun T, Sun WY, Sun X, Sun YJ, Sun YZ, Sun ZT, Tan YH, Tan YX, Tang CJ, Tang GY, Tang J, Tao LY, Tao QT, Tat M, Teng JX, Thoren V, Tian WH, Tian Y, Uman I, Wang B, Wang BL, Wang CW, Wang DY, Wang F, Wang HJ, Wang HP, Wang K, Wang LL, Wang M, Wang MZ, Wang M, Wang S, Wang S, Wang T, Wang TJ, Wang W, Wang WH, Wang WP, Wang X, Wang XF, Wang XL, Wang Y, Wang YD, Wang YF, Wang YH, Wang YQ, Wang Y, Wang Z, Wang ZY, Wang Z, Wei DH, Weidner F, Wen SP, White DJ, Wiedner U, Wilkinson G, Wolke M, Wollenberg L, Wu JF, Wu LH, Wu LJ, Wu X, Wu XH, Wu Y, Wu Z, Xia L, Xiang T, Xiao D, Xiao GY, Xiao H, Xiao SY, Xiao YL, Xiao ZJ, Xie C, Xie XH, Xie Y, Xie YG, Xie YH, Xie ZP, Xing TY, Xu CF, Xu CJ, Xu GF, Xu HY, Xu QJ, Xu XP, Xu YC, Xu ZP, Yan F, Yan L, Yan WB, Yan WC, Yang HJ, Yang HL, Yang HX, Yang L, Yang SL, Yang T, Yang YF, Yang YX, Yang Y, Ye M, Ye MH, Yin JH, You ZY, Yu BX, Yu CX, Yu G, Yu T, Yuan CZ, Yuan L, Yuan SC, Yuan XQ, Yuan Y, Yuan ZY, Yue CX, Zafar AA, Zeng FR, Zeng X, Zeng Y, Zhan YH, Zhang AQ, Zhang BL, Zhang BX, Zhang DH, Zhang GY, Zhang H, Zhang HH, Zhang HH, Zhang HY, Zhang JL, Zhang JQ, Zhang JW, Zhang JX, Zhang JY, Zhang JZ, Zhang J, Zhang J, Zhang LM, Zhang LQ, Zhang L, Zhang P, Zhang QY, Zhang S, Zhang S, Zhang XD, Zhang XM, Zhang XY, Zhang XY, Zhang Y, Zhang YT, Zhang YH, Zhang Y, Zhang Y, Zhang ZH, Zhang ZY, Zhang ZY, Zhao G, Zhao J, Zhao JY, Zhao JZ, Zhao L, Zhao L, Zhao MG, Zhao Q, Zhao SJ, Zhao YB, Zhao YX, Zhao ZG, Zhemchugov A, Zheng B, Zheng JP, Zheng YH, Zhong B, Zhong C, Zhong X, Zhou H, Zhou LP, Zhou X, Zhou XK, Zhou XR, Zhou XY, Zhou YZ, Zhu J, Zhu K, Zhu KJ, Zhu LX, Zhu SH, Zhu SQ, Zhu TJ, Zhu WJ, Zhu YC, Zhu ZA, Zou BS, Zou JH. Precise Measurements of Decay Parameters and CP Asymmetry with Entangled Λ-Λ[over ¯] Pairs. PHYSICAL REVIEW LETTERS 2022; 129:131801. [PMID: 36206435 DOI: 10.1103/physrevlett.129.131801] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/26/2022] [Accepted: 09/01/2022] [Indexed: 06/16/2023]
Abstract
Based on 10 billion J/ψ events collected at the BESIII experiment, a search for CP violation in Λ decay is performed in the difference between CP-odd decay parameters α_{-} for Λ→pπ^{-} and α_{+} for Λ[over ¯]→p[over ¯]π^{+} by using the process e^{+}e^{-}→J/ψ→ΛΛ[over ¯]. With a five-dimensional fit to the full angular distributions of the daughter baryon, the most precise values for the decay parameters are determined to be α_{-}=0.7519±0.0036±0.0024 and α_{+}=-0.7559±0.0036±0.0030, respectively. The Λ and Λ[over ¯] averaged value of the decay parameter is extracted to be α_{avg}=0.7542±0.0010±0.0024 with unprecedented accuracy. The CP asymmetry A_{CP}=(α_{-}+α_{+})/(α_{-}-α_{+}) is determined to be -0.0025±0.0046±0.0012, which is one of the most precise measurements in the baryon sector. The reported results for the decay parameter will play an important role in the studies of the polarizations and CP violations for the strange, charmed and beauty baryons.
Collapse
|
244
|
Du R, Wang T, Lv H, Zou Y, Hou X, Hou N, Zhang P, Li H, Chi G. Shionone-Targeted Pneumolysin to Ameliorate Acute Lung Injury Induced by Streptococcus pneumoniae In Vivo and In Vitro. Molecules 2022; 27:molecules27196258. [PMID: 36234795 PMCID: PMC9573397 DOI: 10.3390/molecules27196258] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2022] [Revised: 09/09/2022] [Accepted: 09/13/2022] [Indexed: 12/02/2022] Open
Abstract
Streptococcus pneumoniae (S. pneumoniae), as a Gram-positive bacterium, can cause severe bacterial pneumonia, and result in high morbidity and mortality in infected people. Meanwhile, isolated drug-resistant S. pneumoniae is growing, which raises concerns about strategies for combatting S. pneumoniae infection. To disturb S. pneumoniae pathogenicity and its drug-resistance, developing novel anti-infective strategies or compounds is urgent. In this study, the anti-infective effect of shionone was explored. A minimum inhibitory concentration (MIC) assay and growth curve determination were performed to evaluate the effect of the tetracyclic triterpenoid compound shionone against S. pneumoniae. Hemolysis tests, western blotting, oligomerization inhibition assays, and molecular docking were carried out to explore the anti-infective mechanism of shionone. Moreover, the protective effect of shionone was also confirmed in a mousepneumonia model. The results showed that the excellent hemolytic inhibitory activity of shionone was observed at less than 8 μg/mL. Meanwhile, shionone could disturb the oligomerization of pneumolysin (PLY) but did not interfere with PLY expression at less than 4 μg/mL. Molecular docking suggested that shionone targeted the ASP-59, ILE-60, THR-57, PHE-344, and ASN-346 amino acid sites to reduce S. pneumoniae pathogenicity. Furthermore, shionone alleviated lung histopathologic injury and decreased lung bacterial colonization in vivo. The above results showed that shionone could bind to the PLY active pocket under the concentrations of 8 μg/mL and neutralize PLY hemolysis activity to reduce S. pneumoniae pathogenicity in vitro and in vivo.
Collapse
|
245
|
Cao MM, Li H, Zha ZQ, Zhou JY, Luo PF, Gong JY, Ma HM, Sun XB, Chen WQ. [Effect evaluation of the primary screening strategy for liver cancer in rural areas of China]. ZHONGHUA ZHONG LIU ZA ZHI [CHINESE JOURNAL OF ONCOLOGY] 2022; 44:990-996. [PMID: 36164703 DOI: 10.3760/cma.j.cn112152-20211031-00800] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/16/2023]
Abstract
Objective: To estimate the effectiveness of the primary screening strategy for liver cancer in rural areas to provide basic information for the optimization and perfection of the technical program for the early detection and treatment of liver cancer. Methods: Residents including males aged 35-64 and females aged 45-64 from 9 counties in rural China between 2013 and 2015 were selected as the target population. The participant was classified into a high-risk and non-high-risk group based on the standardized questionnaire or HBsAg, and the Chi-squared test was applied to compare differences between the two groups. The Cox proportional hazard regression models were applied to assess hazard ratio (HR) and its 95% confidence interval (CI). Results: 358 348 participants were recruited from 2013 to 2015. 1 196 individuals were identified with liver cancer until December 31, 2021, with an incidence density of 52.0/10(5) person-years. Of the participants, 54 650 were assessed as high risk (15.3%) based on the questionnaire and the status of HBsAg. The high-risk population had a higher incidence density (168.3/10(5) person-years vs 31.5/10(5) person-years) and higher risk of developing liver cancer (HR=2.98, 95% CI=2.64-3.35), compared to the non-high-risk group. Based on the questionnaire-based high-risk assessment system, 47 884 (13.4%) individuals were identified as high risk, who showed statistical differences in terms of incidence density and incidence risk, in comparison to the low-risk population (all P<0.05). HBsAg can screen out a higher proportion of high-risk individuals who are women, non-smokers, non-drinkers, and individuals without a family history of liver cancer (all P<0.05). The sensitivity analysis of the effectiveness of the whole primary screening method is stable, and high-risk individuals still had a higher risk of liver cancer. Conclusions: The primary screening method of the questionnaire-based risk assessment system and HBsAg can achieve satisfactory effectiveness. The questionnaire-based risk assessment system could identify high-risk individuals to some extent, however, it still needs to be improved to meet the actual requirements.
Collapse
|
246
|
Sun DQ, Yang F, Li H, Cao MM, Yan XX, He SY, Zhang SL, Xia CF, Chen WQ. [Regional disparities in trends of global gastric cancer incidence and mortality from 1990 to 2019]. ZHONGHUA ZHONG LIU ZA ZHI [CHINESE JOURNAL OF ONCOLOGY] 2022; 44:950-954. [PMID: 36164696 DOI: 10.3760/cma.j.cn112152-20220120-00049] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/16/2023]
Abstract
Objective: To depict gastric cancer burden trends globally and analyze geographical and socioeconomic disparities among different countries and territories. Methods: We extracted the data from Global Burden of Disease 2019 Database. We conducted the Joinpoint regression and calculated the average annual percent change (AAPC) and corresponding 95% confidence interval (CI) for age-standardized gastric cancer incidence and mortality from 1990 to 2019. Linear regression was performed to measure the association of sociodemographic index (SDI) with each country's gastric cancer incidence and mortality AAPC. We applied the age-period-cohort analysis to assess the cohort effect on gastric cancer incidence and mortality. Results: The AAPCs for gastric cancer age-standardized incidence and mortality rates from 1990 to 2019 were -1.27% (95% CI: -1.43%, -1.11%) and -1.87% (95% CI: -2.01%, -1.72%), respectively. SDI levels were negatively associated with AAPCs, which means that countries with higher SDI had higher AAPC (P<0.001). The decrease of gastric cancer burden in countries with low or medium SDI levels was slower than that globally. The age-period-cohort analysis indicated that countries with higher SDI levels had more apparent decline in birth cohort effects from 1900 to 1999. Conclusions: Countries with different socioeconomic levels have various decreasing rates for gastric cancer incidence and deaths. Countries with higher SDI levels have higher declining rates for gastric cancer burden.
Collapse
|
247
|
Chen X, Qi X, Cao Y, Li Y, Li H, Wang Q, Ai J. [Indirubin relieves inflammatory injury of chondrocytes in a mouse model of osteoarthritis]. NAN FANG YI KE DA XUE XUE BAO = JOURNAL OF SOUTHERN MEDICAL UNIVERSITY 2022; 42:1381-1388. [PMID: 36210712 DOI: 10.12122/j.issn.1673-4254.2022.09.15] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
OBJECTIVE To investigate the effect of indirubin for relieving joint inflammation and injury in a rat model of osteoarthritis. METHODS Articular cartilage chondrocytes were isolated from adult rat knee joint and cultured in the presence of interleukin-1β (IL-1β) and 0.1, 0.5, 1.0, or 2.0 μmol/L indirubin. The cells were transfected with NPAS2 siRNA or a non-specific siRNA, and the cell proliferation and apoptosis were evaluated using tetramethylthiazole blue staining and flow cytometry. The protein expression levels of Bax, Bcl-2, ACAN, COL2A1, MMP-13 and NPAS2 were detected with Western blotting, and the levels of NO, PGE2 and TNF-α in the culture supernatant were determined with ELISA. The mRNA expression levels of NPAS2, ACAN, COL2A1 and MMP-13 were detected using fluorescence quantitative PCR. In a C57BL/6 mouse model of osteoarthritis, the effect of indirubin on BAX, Bcl-2, ACAN and MMP-13 protein expressions in the bone and joint tissues were evaluated with Western blotting. RESULTS Treatment with 0.1 μmol/L indirubin produced no significant changes in chondrocyte proliferation, apoptosis, caspase-3 activity, or BAX and Bcl-2 protein expressions. At higher doses (0.5, 1.0 and 2.0 μmol/L), indirubin significantly promoted cell proliferation, increased Bcl-2 protein expression, and lowered cell apoptosis rate, caspase-3 activity and Bax protein expression (P < 0.05). Indirubin treatment at 0.5 μmol/L up-regulated the protein and mRNA expressions of NPAS2, ACAN and COL2A1, and down-regulated the expressions of MMP-13, NO, PGE2 and TNF-α (P < 0.05). Interference of NPAS2 expression significantly attenuated the protective effect of 0.5 μmol/L indirubin against IL-1β-induced chondrocyte injury. The mouse model of osteoarthritis showed obviously increased protein levels of BAX and MMP-13 (P < 0.01) and decreased levels of Bcl-2 (P < 0.05) and ACAN (P < 0.01) in the knee joint, and indirubin treatment of the mouse models significantly inhibited the increase of BAX and MMP-13 protein expressions (P < 0.01) and up-regulated the protein expressions of Bcl-2 and ACAN (P < 0.05). CONCLUSION Indirubin has a protective effect on osteoarthritis tissue and alleviates inflammation and damage of osteoarthritis chondrocytes possibly through NPAS2.
Collapse
|
248
|
Wu T, Lin F, Wang J, Li H, Liu M, Zhang YR, Wang WW, Huang F. [Hepatitis C elimination among drug users in China: challenges, strategies and experiences]. ZHONGHUA GAN ZANG BING ZA ZHI = ZHONGHUA GANZANGBING ZAZHI = CHINESE JOURNAL OF HEPATOLOGY 2022; 30:1002-1006. [PMID: 36299198 DOI: 10.3760/cma.j.cn501113-20210311-00116] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/16/2023]
Abstract
The prevalence of hepatitis C among drug users in China is high, and thus it is one of the populations that needs attention to achieve hepatitis C elimination. However, due to the complexities of this population's situation, hepatitis C elimination still faces many challenges, such as difficult screening, low cure rate, poor compliance, and high reinfection rates. Therefore, the existing diagnostic and therapeutic system cannot meet the needs of this population. China has pledged to establish a unified system for drug users that will integrate drug treatment programs, education, medical care, and rehabilitation, creating favorable conditions for integrating hepatitis C diagnosis and treatment and improving the accessibility of drug users. Starting with the current situation and challenges of eliminating hepatitis C among drug users in China, in combination with cases from other countries, this paper discusses the strategy for eliminating hepatitis C and introduces what Hainan Province did to eliminate hepatitis C among drug users.
Collapse
|
249
|
Ablikim M, Achasov MN, Adlarson P, Ahmed S, Albrecht M, Aliberti R, Amoroso A, An MR, An Q, Bai XH, Bai Y, Bakina O, Ferroli RB, Balossino I, Ban Y, Batozskaya V, Becker D, Begzsuren K, Berger N, Bertani M, Bettoni D, Bianchi F, Bloms J, Bortone A, Boyko I, Briere RA, Brueggemann A, Cai H, Cai X, Calcaterra A, Cao GF, Cao N, Cetin SA, Chang JF, Chang WL, Chelkov G, Chen C, Chen G, Chen HS, Chen ML, Chen SJ, Chen T, Chen XR, Chen XT, Chen YB, Chen ZJ, Cheng WS, Cibinetto G, Cossio F, Cui JJ, Dai HL, Dai JP, Dbeyssi A, de Boer RE, Dedovich D, Deng ZY, Denig A, Denysenko I, Destefanis M, De Mori F, Ding Y, Dong J, Dong LY, Dong MY, Dong X, Du SX, Egorov P, Fan YL, Fang J, Fang SS, Fang Y, Farinelli R, Fava L, Feldbauer F, Felici G, Feng CQ, Feng JH, Fritsch M, Fu CD, Gao H, Gao YN, Gao Y, Garzia I, Ge PT, Geng C, Gersabeck EM, Gilman A, Goetzen K, Gong L, Gong WX, Gradl W, Greco M, Gu MH, Gu YT, Guan CY, Guo AQ, Guo LB, Guo RP, Guo YP, Guskov A, Han TT, Han WY, Hao XQ, Harris FA, He KK, He KL, Heinsius FH, Heinz CH, Heng YK, Herold C, Himmelreich M, Holtmann T, Hou GY, Hou YR, Hou ZL, Hu HM, Hu JF, Hu T, Hu Y, Huang GS, Huang KX, Huang LQ, Huang XT, Huang YP, Huang Z, Hussain T, Hüsken N, Imoehl W, Irshad M, Jackson J, Jaeger S, Janchiv S, Ji Q, Ji QP, Ji XB, Ji XL, Ji YY, Jiang HB, Jiang SS, Jiang XS, Jiang Y, Jiao JB, Jiao Z, Jin S, Jin Y, Jing MQ, Johansson T, Kalantar-Nayestanaki N, Kang XS, Kappert R, Kavatsyuk M, Ke BC, Keshk IK, Khoukaz A, Kiese P, Kiuchi R, Kliemt R, Koch L, Kolcu OB, Kopf B, Kuemmel M, Kuessner M, Kupsc A, Kühn W, Lane JJ, Lange JS, Larin P, Lavania A, Lavezzi L, Lei ZH, Leithoff H, Lellmann M, Lenz T, Li C, Li C, Li CH, Li C, Li DM, Li F, Li G, Li H, Li H, Li HB, Li HJ, Li HN, Li JQ, Li JS, Li JW, Li K, Li LJ, Li LK, Li L, Li MH, Li PR, Li SX, Li SY, Li T, Li WD, Li WG, Li XH, Li XL, Li X, Li ZY, Liang H, Liang H, Liang H, Liang YF, Liang YT, Liao GR, Liao LZ, Libby J, Limphirat A, Lin CX, Lin DX, Lin T, Liu BJ, Liu CX, Liu D, Liu FH, Liu F, Liu F, Liu GM, Liu HB, Liu HM, Liu H, Liu H, Liu JB, Liu JL, Liu JY, Liu K, Liu KY, Liu K, Liu L, Liu MH, Liu PL, Liu Q, Liu SB, Liu T, Liu WK, Liu WM, Liu X, Liu Y, Liu YB, Liu ZA, Liu ZQ, Lou XC, Lu FX, Lu HJ, Lu JG, Lu XL, Lu Y, Lu YP, Lu ZH, Luo CL, Luo MX, Luo T, Luo XL, Lyu XR, Lyu YF, Ma FC, Ma HL, Ma LL, Ma MM, Ma QM, Ma RQ, Ma RT, Ma XY, Ma Y, Maas FE, Maggiora M, Maldaner S, Malde S, Malik QA, Mangoni A, Mao YJ, Mao ZP, Marcello S, Meng ZX, Messchendorp JG, Mezzadri G, Miao H, Min TJ, Mitchell RE, Mo XH, Muchnoi NY, Muramatsu H, Nakhoul S, Nefedov Y, Nerling F, Nikolaev IB, Ning Z, Nisar S, Niu Y, Olsen SL, Ouyang Q, Pacetti S, Pan X, Pan Y, Pathak A, Pathak A, Patteri P, Pelizaeus M, Peng HP, Peters K, Pettersson J, Ping JL, Ping RG, Plura S, Pogodin S, Poling R, Prasad V, Qi H, Qi HR, Qi M, Qi TY, Qian S, Qian WB, Qian Z, Qiao CF, Qin JJ, Qin LQ, Qin XP, Qin XS, Qin ZH, Qiu JF, Qu SQ, Rashid KH, Ravindran K, Redmer CF, Ren KJ, Rivetti A, Rodin V, Rolo M, Rong G, Rosner C, Rump M, Sang HS, Sarantsev A, Schelhaas Y, Schnier C, Schoenning K, Scodeggio M, Shan KY, Shan W, Shan XY, Shangguan JF, Shao LG, Shao M, Shen CP, Shen HF, Shen XY, Shi BA, Shi HC, Shi RS, Shi X, Shi XD, Song JJ, Song WM, Song YX, Sosio S, Spataro S, Stieler F, Su KX, Su PP, Su YJ, Sun GX, Sun H, Sun HK, Sun JF, Sun L, Sun SS, Sun T, Sun WY, Sun X, Sun YJ, Sun YZ, Sun ZT, Tan YH, Tan YX, Tang CJ, Tang GY, Tang J, Tao QT, Teng JX, Thoren V, Tian WH, Tian YT, Uman I, Wang B, Wang DY, Wang HJ, Wang HP, Wang K, Wang LL, Wang M, Wang MZ, Wang M, Wang S, Wang TJ, Wang W, Wang WH, Wang WP, Wang X, Wang XF, Wang XL, Wang YD, Wang YF, Wang YQ, Wang YY, Wang Y, Wang Z, Wang ZY, Wang Z, Wei DH, Weidner F, Wen SP, White DJ, Wiedner U, Wilkinson G, Wolke M, Wollenberg L, Wu JF, Wu LH, Wu LJ, Wu X, Wu XH, Wu Y, Wu Z, Xia L, Xiang T, Xiao H, Xiao SY, Xiao YL, Xiao ZJ, Xie XH, Xie Y, Xie YG, Xie YH, Xie ZP, Xing TY, Xu CF, Xu CJ, Xu GF, Xu QJ, Xu SY, Xu XP, Xu YC, Yan F, Yan L, Yan WB, Yan WC, Yang HJ, Yang HX, Yang L, Yang SL, Yang YX, Yang Y, Yang Z, Ye M, Ye MH, Yin JH, You ZY, Yu BX, Yu CX, Yu G, Yu JS, Yu T, Yuan CZ, Yuan L, Yuan SC, Yuan XQ, Yuan Y, Yuan ZY, Yue CX, Zafar AA, Zeng FR, Zeng X, Zeng Y, Zhan YH, Zhang AQ, Zhang BL, Zhang BX, Zhang GY, Zhang H, Zhang HH, Zhang HH, Zhang HY, Zhang JL, Zhang JQ, Zhang JW, Zhang JY, Zhang JZ, Zhang J, Zhang J, Zhang LM, Zhang LQ, Zhang L, Zhang P, Zhang S, Zhang XD, Zhang XM, Zhang XY, Zhang XY, Zhang Y, Zhang YT, Zhang YH, Zhang Y, Zhang Y, Zhang ZH, Zhang ZY, Zhang ZY, Zhao G, Zhao J, Zhao JY, Zhao JZ, Zhao L, Zhao L, Zhao MG, Zhao Q, Zhao SJ, Zhao YB, Zhao YX, Zhao ZG, Zhemchugov A, Zheng B, Zheng JP, Zheng YH, Zhong B, Zhong C, Zhong X, Zhou H, Zhou LP, Zhou X, Zhou XK, Zhou XR, Zhou XY, Zhu J, Zhu K, Zhu KJ, Zhu LX, Zhu SH, Zhu TJ, Zhu WJ, Zhu WJ, Zhu YC, Zhu ZA, Zou BS, Zou JH. First Observation of the Direct Production of the χ_{c1} in e^{+}e^{-} Annihilation. PHYSICAL REVIEW LETTERS 2022; 129:122001. [PMID: 36179210 DOI: 10.1103/physrevlett.129.122001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/23/2022] [Revised: 06/22/2022] [Accepted: 07/26/2022] [Indexed: 06/16/2023]
Abstract
We study the direct production of the J^{PC}=1^{++} charmonium state χ_{c1}(1P) in electron-positron annihilation by carrying out an energy scan around the mass of the χ_{c1}(1P). The data were collected with the BESIII detector at the BEPCII collider. An interference pattern between the signal process e^{+}e^{-}→χ_{c1}(1P)→γJ/ψ→γμ^{+}μ^{-} and the background processes e^{+}e^{-}→γ_{ISR}J/ψ→γ_{ISR}μ^{+}μ^{-} and e^{+}e^{-}→γ_{ISR}μ^{+}μ^{-} is observed by combining all the data samples. The χ_{c1}(1P) signal is observed with a significance of 5.1σ. This is the first observation of a C-even state directly produced in e^{+}e^{-} annihilation. The electronic width of the χ_{c1}(1P) resonance is determined to be Γ_{ee}=(0.12_{-0.08}^{+0.13}) eV, which is of the same order of magnitude as theoretical calculations.
Collapse
|
250
|
Ablikim M, Achasov MN, Adlarson P, Albrecht M, Aliberti R, Amoroso A, An MR, An Q, Bai XH, Bai Y, Bakina O, Ferroli RB, Balossino I, Ban Y, Batozskaya V, Becker D, Begzsuren K, Berger N, Bertani M, Bettoni D, Bianchi F, Bloms J, Bortone A, Boyko I, Briere RA, Brueggemann A, Cai H, Cai X, Calcaterra A, Cao GF, Cao N, Cetin SA, Chang JF, Chang WL, Chelkov G, Chen C, Chen C, Chen G, Chen HS, Chen ML, Chen SJ, Chen SM, Chen T, Chen XR, Chen XT, Chen YB, Chen ZJ, Cheng WS, Chu X, Cibinetto G, Cossio F, Cui JJ, Dai HL, Dai JP, Dbeyssi A, de Boer RE, Dedovich D, Deng ZY, Denig A, Denysenko I, Destefanis M, De Mori F, Ding Y, Dong J, Dong LY, Dong MY, Dong X, Du SX, Egorov P, Fan YL, Fang J, Fang SS, Fang WX, Fang Y, Farinelli R, Fava L, Feldbauer F, Felici G, Feng CQ, Feng JH, Fischer K, Fritsch M, Fritzsch C, Fu CD, Gao H, Gao YN, Gao Y, Garbolino S, Garzia I, Ge PT, Ge ZW, Geng C, Gersabeck EM, Gilman A, Goetzen K, Gong L, Gong WX, Gradl W, Greco M, Gu LM, Gu MH, Gu YT, Guan CY, Guo AQ, Guo LB, Guo RP, Guo YP, Guskov A, Han TT, Han WY, Hao XQ, Harris FA, He KK, He KL, Heinsius FH, Heinz CH, Heng YK, Herold C, Himmelreich M, Hou GY, Hou YR, Hou ZL, Hu HM, Hu JF, Hu T, Hu Y, Huang GS, Huang KX, Huang LQ, Huang LQ, Huang XT, Huang YP, Huang Z, Hussain T, Hüsken N, Imoehl W, Irshad M, Jackson J, Jaeger S, Janchiv S, Ji Q, Ji QP, Ji XB, Ji XL, Ji YY, Jia ZK, Jiang HB, Jiang SS, Jiang XS, Jiang Y, Jiao JB, Jiao Z, Jin S, Jin Y, Jing MQ, Johansson T, Kalantar-Nayestanaki N, Kang XS, Kappert R, Kavatsyuk M, Ke BC, Keshk IK, Khoukaz A, Kiese P, Kiuchi R, Kliemt R, Koch L, Kolcu OB, Kopf B, Kuemmel M, Kuessner M, Kupsc A, Kühn W, Lane JJ, Lange JS, Larin P, Lavania A, Lavezzi L, Lei ZH, Leithoff H, Lellmann M, Lenz T, Li C, Li C, Li CH, Li C, Li DM, Li F, Li G, Li H, Li H, Li HB, Li HJ, Li HN, Li JQ, Li JS, Li JW, Li K, Li LJ, Li LK, Li L, Li MH, Li PR, Li SX, Li SY, Li T, Li WD, Li WG, Li XH, Li XL, Li X, Liang H, Liang H, Liang H, Liang YF, Liang YT, Liao GR, Liao LZ, Libby J, Limphirat A, Lin CX, Lin DX, Lin T, Liu BJ, Liu CX, Liu D, Liu FH, Liu F, Liu F, Liu GM, Liu H, Liu HB, Liu HM, Liu H, Liu H, Liu JB, Liu JL, Liu JY, Liu K, Liu KY, Liu K, Liu L, Liu L, Liu MH, Liu PL, Liu Q, Liu SB, Liu T, Liu WK, Liu WM, Liu X, Liu Y, Liu YB, Liu ZA, Liu ZQ, Lou XC, Lu FX, Lu HJ, Lu JG, Lu XL, Lu Y, Lu YP, Lu ZH, Luo CL, Luo MX, Luo T, Luo XL, Lyu XR, Lyu YF, Ma FC, Ma HL, Ma LL, Ma MM, Ma QM, Ma RQ, Ma RT, Ma XY, Ma Y, Maas FE, Maggiora M, Maldaner S, Malde S, Malik QA, Mangoni A, Mao YJ, Mao ZP, Marcello S, Meng ZX, Messchendorp JG, Mezzadri G, Miao H, Min TJ, Mitchell RE, Mo XH, Muchnoi NY, Nefedov Y, Nerling F, Nikolaev IB, Ning Z, Nisar S, Niu Y, Olsen SL, Ouyang Q, Pacetti S, Pan X, Pan Y, Pathak A, Pelizaeus M, Peng HP, Peters K, Ping JL, Ping RG, Plura S, Pogodin S, Prasad V, Qi FZ, Qi H, Qi HR, Qi M, Qi TY, Qian S, Qian WB, Qian Z, Qiao CF, Qin JJ, Qin LQ, Qin XP, Qin XS, Qin ZH, Qiu JF, Qu SQ, Qu SQ, Rashid KH, Redmer CF, Ren KJ, Rivetti A, Rodin V, Rolo M, Rong G, Rosner C, Ruan SN, Sang HS, Sarantsev A, Schelhaas Y, Schnier C, Schoenning K, Scodeggio M, Shan KY, Shan W, Shan XY, Shangguan JF, Shao LG, Shao M, Shen CP, Shen HF, Shen XY, Shi BA, Shi HC, Shi JY, Shi QQ, Shi RS, Shi X, Shi XD, Song JJ, Song WM, Song YX, Sosio S, Spataro S, Stieler F, Su KX, Su PP, Su YJ, Sun GX, Sun H, Sun HK, Sun JF, Sun L, Sun SS, Sun T, Sun WY, Sun X, Sun YJ, Sun YZ, Sun ZT, Tan YH, Tan YX, Tang CJ, Tang GY, Tang J, Tao LY, Tao QT, Tat M, Teng JX, Thoren V, Tian WH, Tian Y, Uman I, Wang B, Wang BL, Wang CW, Wang DY, Wang F, Wang HJ, Wang HP, Wang K, Wang LL, Wang M, Wang MZ, Wang M, Wang S, Wang S, Wang T, Wang TJ, Wang W, Wang WH, Wang WP, Wang X, Wang XF, Wang XL, Wang Y, Wang YD, Wang YF, Wang YH, Wang YQ, Wang Y, Wang Z, Wang ZY, Wang Z, Wei DH, Weidner F, Wen SP, White DJ, Wiedner U, Wilkinson G, Wolke M, Wollenberg L, Wu JF, Wu LH, Wu LJ, Wu X, Wu XH, Wu Y, Wu YJ, Wu Z, Xia L, Xiang T, Xiao D, Xiao GY, Xiao H, Xiao SY, Xiao YL, Xiao ZJ, Xie C, Xie XH, Xie Y, Xie YG, Xie YH, Xie ZP, Xing TY, Xu CF, Xu CJ, Xu GF, Xu HY, Xu QJ, Xu XP, Xu YC, Xu ZP, Yan F, Yan L, Yan WB, Yan WC, Yang HJ, Yang HL, Yang HX, Yang L, Yang SL, Yang T, Yang YF, Yang YX, Yang Y, Ye M, Ye MH, Yin JH, You ZY, Yu BX, Yu CX, Yu G, Yu T, Yuan CZ, Yuan L, Yuan SC, Yuan XQ, Yuan Y, Yuan ZY, Yue CX, Zafar AA, Zeng FR, Zeng X, Zeng Y, Zhan YH, Zhang AQ, Zhang BL, Zhang BX, Zhang DH, Zhang GY, Zhang H, Zhang HH, Zhang HH, Zhang HY, Zhang JL, Zhang JQ, Zhang JW, Zhang JX, Zhang JY, Zhang JZ, Zhang J, Zhang J, Zhang LM, Zhang LQ, Zhang L, Zhang P, Zhang QY, Zhang S, Zhang S, Zhang XD, Zhang XM, Zhang XY, Zhang XY, Zhang Y, Zhang YT, Zhang YH, Zhang Y, Zhang Y, Zhang ZH, Zhang ZY, Zhang ZY, Zhao G, Zhao J, Zhao JY, Zhao JZ, Zhao L, Zhao L, Zhao MG, Zhao Q, Zhao SJ, Zhao YB, Zhao YX, Zhao ZG, Zhemchugov A, Zheng B, Zheng JP, Zheng YH, Zhong B, Zhong C, Zhong X, Zhou H, Zhou LP, Zhou X, Zhou XK, Zhou XR, Zhou XY, Zhou YZ, Zhu J, Zhu K, Zhu KJ, Zhu LX, Zhu SH, Zhu SQ, Zhu TJ, Zhu WJ, Zhu YC, Zhu ZA, Zou BS, Zou JH. Evidence for a Neutral Near-Threshold Structure in the K_{S}^{0} Recoil-Mass Spectra in e^{+}e^{-}→K_{S}^{0}D_{s}^{+}D^{*-} and e^{+}e^{-}→K_{S}^{0}D_{s}^{*+}D^{-}. PHYSICAL REVIEW LETTERS 2022; 129:112003. [PMID: 36154413 DOI: 10.1103/physrevlett.129.112003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/26/2022] [Revised: 06/17/2022] [Accepted: 06/30/2022] [Indexed: 06/16/2023]
Abstract
We study the processes e^{+}e^{-}→K_{S}^{0}D_{s}^{+}D^{*-} and e^{+}e^{-}→K_{S}^{0}D_{s}^{*+}D^{-}, as well as their charge conjugated processes, at five center-of-mass energies between 4.628 and 4.699 GeV, using data samples corresponding to an integrated luminosity of 3.8 fb^{-1} collected by the BESIII detector at the BEPCII storage ring. Based on a partial reconstruction technique, we find evidence of a structure near the thresholds for D_{s}^{+}D^{*-} and D_{s}^{*+}D^{-} production in the K_{S}^{0} recoil-mass spectrum, which we refer to as the Z_{cs}(3985)^{0}. Fitting with a Breit-Wigner line shape, we find the mass of the structure to be (3992.2±1.7±1.6) MeV/c^{2} and the width to be (7.7_{-3.8}^{+4.1}±4.3) MeV, where the first uncertainties are statistical and the second are systematic. The significance of the Z_{cs}(3985)^{0} signal is found to be 4.6σ including both the statistical and systematic uncertainty. We report the Born cross section multiplied by the branching fraction at different energy points. The mass of the Z_{cs}(3985)^{0} is close to that of the Z_{cs}(3985)^{+}. Assuming SU(3) symmetry, the cross section of the neutral channel is consistent with that of the charged one. Hence, we conclude that the Z_{cs}(3985)^{0} is the isospin partner of the Z_{cs}(3985)^{+}.
Collapse
|